AHA Scientific Statement

Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus
A Scientific Statement From the American Heart Association

David M. Maahs, MD, PhD, Co-Chair; Stephen R. Daniels, MD, PhD, FAHA;
Sarah D. de Ferranti, MD; Helén L. Dichek, MD; Joseph Flynn, MD, MS;
Benjamin I. Goldstein, MD, PhD; Aaron S. Kelly, PhD, FAHA; Kristen J. Nadeau, MD, MS;
Pamela Martyn-Nemeth, RN, PhD; Stavroula K. Osganian, MD, ScD;
Laurie Quinn, PhD, RN, FAHA; Amy S. Shah, MD, MS;
Elaine Urbina, MD, MS, FAHA, Chair; on behalf of the American Heart Association Atherosclerosis,
Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young,
Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council for High
Blood Pressure Research, and Council on Lifestyle and Cardiometabolic Health

The rates of both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are increasing in youth.[1] In the past 10 years, guidelines for the identification and management of cardiovascular disease (CVD) risk factors in youth with diabetes mellitus have been published by multiple professional organizations, including the American Diabetes Association (ADA),[2,3] the American Heart Association (AHA),[4,5] the American Academy of Pediatrics,[6] the International Society of Pediatric and Adolescent Diabetes (ISPAD),[7] and the Pediatric Cardiovascular Risk Reduction Initiative.[8] This scientific statement summarizes and interprets these guidelines and new developments in the field in the past decade and outlines future research and clinical needs to improve cardiovascular health and risk factor management in youth with diabetes mellitus. Additional goals for this statement are to increase awareness of CVD risk factors and their identification, prevention, and treatment and to improve cardiovascular health in youth with diabetes mellitus by encouraging advancement in research and clinical care, including understanding and implementing current CVD guidelines. Improving cardiovascular health in youth with diabetes mellitus has important public health implications; therefore, this statement aims to reach healthcare

providers in diabetes mellitus, cardiology, and related fields. (Note: The sections within this scientific statement are organized by diabetes mellitus type, when possible, with brief summary statements concluding each section. Multiple definitions for CVD are used in the cited articles. Readers of this statement should include risk factors, surrogate markers, and end-organ damage under this umbrella term of CVD.)

Scope of Problem

Type 1 Diabetes Mellitus

Multiple studies document an increase of 2% to 5% annually in the incidence of T1DM worldwide.[9] The SEARCH for Diabetes in Youth (SEARCH) study estimated that there were 166 018 to 179 388 youth with T1DM in the United States in 2010.[1] Worldwide, rates of T1DM differ as a result of variation in the genetics of autoimmunity, exposure to environmental triggers, and healthcare infrastructure differences with a resultant spectrum of survival at diagnosis and subsequent life span.[9] The rapid and sustained increase in T1DM suggests an environmental cause or genetic-environmental interaction because genetic shifts in such a short time period are unlikely.

The cause of T1DM is the subject of multiple ongoing studies with the shared goal of identifying targets for prevention.[10,11] A cure is likely still far in the future, barring dramatic scientific breakthroughs, underscoring the need to improve cardiovascular health for people with T1DM.

Two- to 10-fold increases in rates of coronary heart disease and death resulting from coronary heart disease in T1DM were reported in multiple studies involving adults.[12–16] Despite some improvement in CVD risk factors and mortality for people with T1DM, these rates remain higher than in the nondiabetic population.[17–19] Multiple CVD risk factors exist in T1DM, with glucose control commonly considered to be the critical factor accounting for increased risk compared with nondiabetics. Although data from epidemiologic studies on glucose control in T1DM and CVD are inconclusive,[20] the Diabetes Control and Complications Trial–Epidemiology of Diabetes Complications (DCCT/EDIC) trial reported a 57% reduction in CVD in the intensively managed compared with the conventional arm after 17 years of follow-up.[21] However, although renal outcomes have greatly improved in people with T1DM, CVD outcomes lag behind, arguing that unaddressed risk factors exist and require further study. In the general population, female individuals have lower CVD risk than male individuals. However, this protective effect of female sex is lost with T1DM; CVD risk in female individuals approaches that of male individuals.[17,22–24] CVD risk factor management in T1DM needs to be improved.

Type 2 Diabetes Mellitus

Before the 1990s, T2DM was rarely diagnosed in youth,[25] but increased rates now parallel the increasing rates of pediatric obesity.[26] Although rates of T2DM in youth have increased in recent decades, T2DM continues to be less common than T1DM. The SEARCH study estimated that there were between 20 203 and 22 820 youth with T2DM in the United States in 2010 compared with 166 018 to 179 388 with T1DM.[1] By 2050, the prevalence of T2DM in youth is estimated to be 30 111 to 84 131, constituting 10% to 15% of all diabetes mellitus in youth in the United States.[1] Among non-Hispanic black (NHB), Hispanic, Asian-Pacific Islander, American Indian, and Alaska Native populations, the proportion of youth with T2DM is higher than in non-Hispanic whites (NHWs).[1]

Data on outcomes for people diagnosed with T2DM in childhood are limited compared with T1DM. However, existing data suggest increased rates of vascular disease,[27] including CVD.[28] Data for adults with diabetes mellitus from the Framingham Heart Study indicate a reduction in all-cause mortality from 1950 to 2005, but mortality remains twice as high and CVD mortality 3 times higher compared with nondiabetics.[29] A recent study from Australia reports greater mortality, more complications, and worse CVD risk factors in youth-onset T2DM than T1DM despite similar glucose control and shorter diabetes mellitus duration.[30] Great concern exists about future outcomes for youth diagnosed with T2DM in childhood,[31] with healthy weight and CVD risk factor management as priorities.

Duration of diabetes mellitus is consistently and not unexpectedly a risk factor for diabetic complications in general and for CVD specifically. For example, a 20- or 30-year duration of T1DM confers an increased risk for CVD compared with a similarly aged and controlled patient who is recently diagnosed. Moreover, concern exists that the duration of T2DM diagnosed in childhood may translate into early development of diabetic complications, including CVD.[30,31]

Racial/Ethnic Disparities

Type 1 Diabetes Mellitus

Disparities can be defined as differences in frequency, treatment, or outcomes for the disease based on race or ethnicity. T1DM affects far more NHW children than any other racial/ethnic group,[32] likely because of genetic differences in autoimmunity. Among youth <10 years of age, almost all diabetes mellitus cases are T1DM, regardless of race/ethnicity.

Although T1DM is more common in NHWs, minority youth with T1DM are reported to have poorer glucose control, more diabetes mellitus–related complications, and higher mortality.[33,34] For example, the T1D Exchange found that more minority children have diabetic ketoacidosis, kidney disease, CVD risk factors, and diabetes mellitus–associated mortality[33] and that NHW race was significantly associated with lower hemoglobin A_{1c} (HbA$_{1c}$).[32] Specifically, only 14% of NHB participants currently meet the ADA's HbA$_{1c}$ target compared with 34% and 28% in NHW and Hispanic participants, respectively.[35]

One potential contributor to the racial/ethnic disparities in T1DM is that NHW youth with T1DM report higher self-monitoring blood glucose checks per day, a behavior that predicts better diabetes mellitus control.[36] In addition, in the T1D Exchange, significantly fewer Hispanic and NHB children used insulin pumps compared with NHW children, with pump use in NHB youth being significantly less than in Hispanic youth.[38] Even in the groups with the highest education, socioeconomic status, and insurance, NHB youth still had lower pump use.[38] In addition, differences in insulin resistance (IR) are another possible factor. Danielson et al[39] showed that IR was significantly lower in NHW youth than in minority youth with T1DM.

Type 2 Diabetes Mellitus

Racial disparities in T2DM have similarities and differences compared with T1DM. The major difference is that minority youth are much more likely to develop T2DM. The incidence of T2DM is the highest among youth who are American Indian (25.3 and 49.4 per 100 000 per year for those 10–14 and 15–19 years of age, respectively), followed by NHB (22.3 and 19.4 per 100 000 per year), Asian/Pacific Islander (11.8 and 22.7 per 100 000 per year), and Hispanic (8.9 and 17.0 per 100 000 per year), and lowest (3.0 and 5.6 per 100 000 per year) among NHW.[40] Second, minority youth have higher rates of obesity, hypertension, dyslipidemia, and other metabolic syndrome components associated with T2DM[41] and have higher HbA$_{1c}$, more CVD risk factors, and higher rates of diabetic ketoacidosis.[42] In particular, NHB adolescents are more likely to have hypertension, arterial stiffness, and higher C-reactive protein,[42,43] all possible explanations for the higher rates of myocardial infarction and stroke seen in NHB adults.[44] Another report shows higher intramyocellular lipid in both NHB and Hispanic youth compared with NHW youth.[45]

However, the picture is complicated. Age, lipids, blood pressure (BP), and duration of T2DM were differently associated with arterial stiffness in each racial/ethnic group, implying

different mechanisms of cardiovascular risk.[42] In addition, despite high rates of T2DM and CVD, NHB youth have a lower prevalence of hypertriglyceridemia,[46–48] decreased insulin sensitivity, yet upregulated β-cell function relative to insulin sensitivity,[49] less visceral fat,[45,50,51] and less hepatic fat, with rates of hepatic fat highest in Hispanic male adolescents.[52,53] Finally, although few data exist on racial/ethnic differences in renal function in youth with T2DM, data in adults show that racial/ethnic minorities were more likely to have proteinuric diabetic kidney disease and less likely to have nonproteinuric diabetic kidney disease.[54]

Thus, diabetes mellitus disproportionately affects particular racial/ethnic groups in frequency, treatment, and outcomes. Further exploring potential mechanisms, including disparities in care and physiological variation, may contribute to preventing race/ethnicity–associated disparities and allow targeted treatments.

Overview of Current Guidelines

Multiple guidelines, with a variety of evidence or opinion-based strategies, exist that are relevant to achieving CVD risk reduction in youth with diabetes mellitus. These guidelines include an overarching document on pediatric CVD risk,[8] scientific statements related to specific risk factors,[6] management guidelines on diabetes mellitus in children,[3,7,55] and a guideline focusing specifically on dyslipidemia in pediatric diabetes mellitus.[2] In general, the published guidelines are consistent in that major targets for CVD risk reduction include glucose control, hypertension, and dyslipidemia; recommendations for these CVD risk factors are summarized in Table 1. However, approaches to risk factor reduction and target levels differ. One area of difference between guidelines is the use of pharmacotherapy in patients with low-density lipoprotein (LDL) cholesterol (LDL-c) of 100 to 130 mg/dL who are resistant to lifestyle counseling. A second area of guideline divergence concerns dyslipidemia screening and treatment recommendations for T1DM versus T2DM. The 2003 ADA statement "Management of Dyslipidemia in Children and Adolescents With Diabetes"[2] recommends screening for lipid disorders more frequently in T2DM than in T1DM. A somewhat more substantive difference is in the AHA statement "Cardiovascular Risk Reduction in High-Risk Pediatric Patients"[4] which considers T1DM to be a higher-risk condition than T2DM and therefore uses different treatment targets based on the risk tier designation. However, the more recent National Institutions of Health statement elevates T2DM to the same risk status as T1DM and may be considered to supersede the previous recommendation.[8] Emerging data from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study and others[30] will inform future scientific statements and guidelines[60] and suggest accelerated risk in T2DM. Another place where guidelines diverge is around goals for HbA$_{1c}$, with the ADA setting age-specific targets of 8.5% (<6 years of age), 8% (6–12 years of age), and 7.5% (13–18 years of age),[56] whereas ISPAD recommends a target of <7.5% for all children with diabetes mellitus.[61]

Pediatric guidelines also address behavioral risk factors, including smoking, physical activity (PA), diet, and weight management. All guidelines recommend screening for cigarette smoke exposure and offering smoking cessation services. In the 2006 AHA statement on the management of high-risk pediatric patients, Kavey et al[4] recommended obtaining a parental smoking history at every visit and a patient smoking history starting at 10 years of age. Exercise is promoted in all guidelines. The ADA 2005 T1DM statement recommends 30 to 60 minutes of moderate PA per day. The 2006 AHA statement[4] recommends ≥1 h/d of active play and ≤2 h/d of screen time. All guidelines for care of the child with diabetes mellitus recommend following a healthy diet; none target poor diet as an independent CVD risk factor. Instead, dietary improvement is recommended for treatment of CVD risk factors (low saturated fat for high LDL-c, low salt for hypertension). A lower-carbohydrate diet is the recommendation for high triglyceride levels in several guidelines. Obesity is also recognized as a contributing factor to CVD risk in that treatment of obesity is recommended for children with both T1DM and T2DM who have hyperlipidemia or hypertension. IR is a fundamental physiological process underpinning T2DM and a component of T1DM; however, the optimal measurement methodology is not clear, and none of the guidelines make specific recommendations about testing for IR. Similarly, inflammation is not recommended as a specific screening metric or therapeutic target in pediatric diabetes mellitus guidelines, although it is recognized as an important pathophysiological process in atherosclerosis.

Adherence to these guidelines was assessed in several studies, although most publications focus primarily on glucose management and less on screening for secondary complications related to CVD risk reduction.[62] A study in the United Kingdom found 83.5% compliance with lipid screening with T1DM,[63] and another in children with T2DM found that only half of the patients had lipid testing.[64] In a survey by Gosden et al,[65] only 66% of patients had their BP checked yearly, and other CVD risk factors were not addressed. The SEARCH study reported self-assessed adherence to guidelines in 1514 participants.[66] Those investigators reported that BP was checked at most or all visits in the majority of patients (95%), that lipid screening was done in 88% of patients but less commonly in the older T2DM patients (69%), and that BP measurement, although more common than lipid screening, was also less frequent in this population. The ADA statement on transition of pediatric diabetes mellitus patients to adult care noted that pediatric providers tend to use general guidelines for screening and treatment of lipid disorders, whereas adult providers use diabetes mellitus–specific guidelines.[67]

Since publication of the pediatric guidelines, large epidemiological studies have reported the frequency and current management of CVD risk factors in youth with both T1DM and T2DM. These studies make it clear that elevated traditional CVD risk factors such as HbA$_{1c}$, BP, and cholesterol are common. Moreover, the epidemiological data suggest that few youth with diabetes mellitus receive BP- or lipid-lowering medications as recommended by the guidelines (Table 2). It is important to note that these data were published relatively soon after the various CVD in diabetes mellitus guidelines were issued and may not reflect current practice in pediatric diabetes mellitus. More recently, the T1D Exchange reported that 4.4% of youth had the clinical diagnosis of microalbuminuria, but only 36% were treated with angiotensin-converting enzyme/angiotensin receptor blocker therapy.[71] The past decade has seen progression in knowledge and awareness of

Table 1. Summary of Guideline Recommendations Relevant to Pediatric Diabetes Mellitus

Guideline by Topic	Who Should Be Screened	How to Screen	Action Cut Points	Recommended Action	Differences in Recommendations Between T1DM and T2DM
Glucose control					
AHA cardiovascular risk reduction in high-risk pediatric patients (2006)[4]	All	Frequent HbA$_{1c}$, per ADA guidelines	No diagnosis or age differences, goal >7%	Intensify glucose control	None
ADA (2013)[56]	All	HbA$_{1c}$ every 3 mo	Age 0–6 y >8.5%; Age 6–12 y >8%; Age 13–19 y >7.5%	Intensify glucose control	None
ADA (2005)[3]	All	HbA$_{1c}$	Age 0–6 y >8.5% (and <7.5%); Age 6–12 y >8%; Age 13–19 y >7.5%	Intensify glucose control	N/A
ISPAD (2011)[7]	All	HbA$_{1c}$ 4–6 times per y for younger children, 3–4 times per y in older children, 2–4 times per y in adolescents	All ages >7.5%	Intensify glucose control	None
Lipid abnormalities					
AHA cardiovascular risk reduction in high-risk pediatric patients (2006)[4]	Not specified	Fasting lipid profile	T1DM LDL >100 mg/dL; T2DM LDL >130 mg/dL	Step 1 diet* for 6 mo; statins if >10 y and LDL not at cut point despite 6 mo of lifestyle therapy	Lower LDL cut point in T1DM vs T2DM; T1DM is a tier 1 risk condition, T2DM is a tier 2 (lower risk)
			TG 150–400 mg/dL; TG >700–1000 mg/dL	Low-fat, low-simple-carbohydrate diet and weight loss if necessary; consider niacin or fibrate	T1DM is a tier 1 risk condition, T2DM is a tier 2 (lower risk)
ADA (2013)[56]	>2 y at time of diagnosis if there is a family history of early CVD; ≥10 y of no family history; if LDL is <100 mg/dL at screening, recheck every 5 y	Fasting lipid profile once glucose is controlled	LDL >100 mg/dL	Lifestyle change, step 2 diet, with <7% of calories from saturated fat and dietary cholesterol <200 mg/dL; statins: if child is without risk factors aside from T1DM and LDL >160 mg/dL despite lifestyle therapy; if child has additional risk factors (including family history of early CVD) and LDL >130 mg/dL despite 6 mo of lifestyle therapy; goal of therapy is <100 mg/dL	None (T2DM less well specified)
ADA T1DM (2005)[3]	>2 y at time of diagnosis if there is a family history of early CVD or high cholesterol (TC >240 mg/dL); if no family history, screen at puberty (age >12 y); repeat every 5 y	Fasting lipid profile, once glucose is controlled	LDL >100 mg/dL	LDL 100–129 mg/dL: maximize nonpharmacological treatment: optimize glucose control, reduce weight if necessary, increase exercise, and decrease dietary saturated fat. Role of statins is unclear. LDL 130–159 mg/dL: statins are recommended; LDL >160 mg/dL: statins are strongly recommended; medication target: LDL <100 mg/dL	N/A

(Continued)

Table 1. Continued

Guideline by Topic	Who Should Be Screened	How to Screen	Action Cut Points	Recommended Action	Differences in Recommendations Between T1DM and T2DM
Lipid abnormalities (continued)					
ADA management of dyslipidemia in children and adolescents with diabetes (2003)[2]	>2 y at time of diagnosis if there is a family history of early CVD or high cholesterol (TC >240 mg/dL); if no family history, screen at puberty (age >12 y); if normal, screen every 5 y in T1DM, every 2 y in T2DM	Fasting lipid profile, once glucose is controlled	LDL >100 mg/dL; TG >150 mg/dL; HDL <35 mg/dL	Repeat abnormal values; LDL 100–129mg/dL: maximize nonpharmacological treatment: optimize glucose control, reduce weight if necessary, increase exercise, and decrease dietary saturated fat; LDL 130–159 mg/dL: consider statins based on total cardiovascular risk picture; LDL >160 mg/dL: treat with statins; medication target: LDL <100 mg/dL	Lipid screening is more frequent (every 2 y) for T2DM than T1DM (every 5 y)
ISPAD (2011)[7]	≥2 y if there is a family history, otherwise >12 y		LDL >100 mg/dL	Lifestyle is main treatment; statins should be considered if LDL >100mg/dL although long-term safety is not known	
AAP (2008)[6]	≥2 y, repeated every 3–5 y if normal	Fasting lipid profile	LDL ≥130 mg/dL	Lifestyle for 6 mo; statins for children age ≥8 y of age if LDL ≥130 mg/dL despite 6 mo of lifestyle therapy; target LDL: 110–130 mg/dL	
AAP management of T2DM in children and adolescents (2013)[57]	T2DM	Fasting lipid profile once under glucose control, then every 2 y	LDL ≥130 mg/dL	Dietary advice by a dietician; follow diet <30% calories from fat, <7% calories from saturated fat, cholesterol intake <200 mg/d, and avoidance of *trans* fats; LDL measurements; weight loss efforts if necessary; if LDL ≥130 mg/dL: statins; LDL target: <100 mg/dL	N/A
			TG 150–600 mg/dL; TG ≥700 mg/dL	Low glycemic index diet; fibrates or niacin	N/A
NHLBI (2011)[58]	T1DM: all; T2DM: all; any age	Average of 2 FLPs	LDL ≥130 mg/dL; Age <10 y, TG ≥100 mg/dL; Age ≥10 y, TG ≥130 mg/dL	Lifestyle therapy: Begin with CHILD1. If insufficient response move to CHILD2-LDL for high LDL, CHILD2-TG for high TGs Statins: Age 10 y and LDL ≥160 mg/dL without other RF, ≥130 mg/dL with 2 additional moderate RF or family history; in the case of extremely high lipid levels, medications may be considered in children ages 8–10 y under the supervision of a lipid specialist	No distinction made between T1DM and T2DM with regard to risk or treatment of lipid disorders
Hypertension					
AHA cardiovascular risk reduction in high-risk pediatric patients (2006)[4]	All patients	BP taken with proper technique at every encounter	SBP or DBP >90th percentile for age, sex, and height percentile or >120/80 mm Hg, whichever is lower; SBP or DBP >95th percentile on 3 occasions	Lifestyle therapy for 6 mo. ACE inhibitor if SBP remains >95th percentile. Goal on medications is BP >130/80 mm Hg or >95th percentile, whichever is lower; medications per fourth report	ACE inhibitor recommended specifically for T1DM, medication choice for T2DM not specified

(Continued)

Table 1.   Continued

Guideline by Topic	Who Should Be Screened	How to Screen	Action Cut Points	Recommended Action	Differences in Recommendations Between T1DM and T2DM
Hypertension (continued)					
AAP management of T2DM in children and adolescents (2013)[57]	All T2DM patients	Check BP at every visit	>95th percentile	Initial treatment lifestyle modification; ACE inhibitor if the BP remains >95th percentile	N/A
ADA (2013)[56]	All patients		>90th percentile for age, sex, and height percentiles, persistent on 3 separate measurements with proper technique; >95th percentile or 130/80 mm Hg, whichever is lower	Lifestyle first for 3–6 mo, then medication. Medications as first treatment. ACE inhibitor is first line	
ADA T1DM (2005)[3]	All T1DM	Check BP at every visit using standard techniques	>90th percentile for age, sex, and height percentiles, persistent on 3 separate measurements with proper technique; >95th percentile or 130/80 mm Hg, whichever is lower	Diet low in salt Increased physical activity; glucose control; ACE inhibitor if lifestyle therapy for 6 mo does not sufficiently lower BP	N/A
ISPAD (2011)[7]	T1DM: all; T2DM: all	At least yearly	>95th percentile for children, 130/80 mm Hg for adults	ACE inhibitors	
NHLBI (2011)[58]	T1DM: all; T2DM: all	Auscultative BP at every medical encounter	>90th percentile for age, sex, and height percentiles, persistent on 3 separate measurements with proper technique; >95th percentile or 120/80 mm Hg, whichever is lower	Diet low in salt Increased physical activity; glucose control; ACE inhibitor if lifestyle therapy for 6 mo does not sufficiently lower BP	
"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents" (2004)[59]	T1DM: all; T2DM: all	Auscultative BP at every medical encounter	Prehypertension: 90th to <95th percentile or >120/80 mm Hg, whichever is lower	Lifestyle for any level of BP; consider pharmacotherapy even with prehypertension; pharmacotherapy with stage 1 and stage 2 hypertension; consider ACE or ARB as first-line pharmacotherapy	None
Obesity					
AHA cardiovascular risk reduction in high-risk pediatric patients (2006)[4]	T1DM and T2DM	Assess BMI at every encounter	T1DM ≥85th percentile; T2DM ≥90th percentile	Diet, weight follow-up every 2–4 wk for 6 mo; if unsuccessful in reaching target in 6 mo, refer to intensive weight management program	Lower BMI target for T1DM than T2DM (85th vs 90th percentile)

AAP indicates American Academy of Pediatrics; ACE angiotensin-converting enzyme; ADA, American Diabetes Association; AHA, American Heart Association; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CHILD1/CHILD2, Cardiovascular Health Integrated Lifestyle Diet; CVD, cardiovascular disease; DBP, diastolic blood pressure; FLP, fasting lipid profile; HDL, high-density lipoprotein; ISPAD, International Society for Pediatric and Adolescent Diabetes; LDL, low-density lipoprotein; N/A, not applicable; NHLBI, National Heart, Lung, and Blood Institute; RF, risk factor; SBP, systolic blood pressure; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TC, total cholesterol; and TG, triglycerides.

*Nutritionist training for step 1 diet, goal <30% of calories from fat, <7% of calories from saturated fat, cholesterol <200 mg/d, avoidance of *trans* fats.

CVD as an important issue in pediatric diabetes mellitus. The first set of guidelines has raised the awareness of CVD risk in youth with diabetes mellitus and descriptive data on rates of CVD risk factors. Reports of low rates of pharmacological treatment have followed. Increased implementation of clinical guidelines needs to be a priority among youth with diabetes

Table 2. Prevalence (%) of Hypertension and Dyslipidemia Diagnosis and Pharmacological Treatment

Study	Hypertension	Rx Treatment	Dyslipidemia	Rx Treatment
SEARCH[68,69]		1.5 total		1 total
T1DM (n=2165)	5.9		15	
T2DM (n=283)	23.7		24	
DPV[70]				
T1DM (n=27 358)	8.1	2.1	28.6	0.4

DPV indicates Diabetes Patientien Verlaufsdokumentation; Rx, prescription medication; T1DM, type 1 diabetes mellitus; and T2DM, type 2 diabetes mellitus.

mellitus. Evidence-based guidelines to promote greater consistency in the approaches to risk factor management and risk factor cut points will be critical to achieving this goal. Such guidelines can be achieved only by gaining a better understanding of the pathophysiology for CVD and risk factor progression in youth with diabetes mellitus.

Current Research

Data from a number of ongoing large, multicenter, observational and interventional research studies are referenced in this statement. Brief descriptions of these studies are provided in the online-only Data Supplement.

Target Organ Damage

The relationship between CVD risk factors and CVD events has been well described in the Framingham Heart Study.[72] Subjects from pediatric longitudinal studies have not aged sufficiently to have suffered CVD events, but the Bogalusa Heart Study,[73] Muscatine study,[74] and Cardiovascular Risk in Young Finn study[75] demonstrated tracking of risk factors from childhood to adulthood and a strong relationship between CVD risk factors measured in healthy children and markers of atherosclerosis, including carotid intima-media thickness (cIMT), measured in adulthood.[76] New evidence suggests that youth with diabetes mellitus can develop target organ damage starting in adolescence.

Echocardiography is recommended by both adult[77] and pediatric[58] guidelines for the evaluation of CVD risk factor–related target organ damage. The prevalence of left ventricular hypertrophy in adults with T2DM is high (23%).[78] Higher left ventricular mass in people with diabetes mellitus predicts decline in kidney[79,80] and cardiac[81,82] function and was an independent predictor of hard cardiovascular events in adults with T2DM.[83]

Similarly, Nadeau et al[84] found higher body size–indexed left ventricular mass in adolescents with T1DM compared with control subjects. Abnormal ambulatory BP patterns were also associated with higher left ventricular mass in youth with T1DM.[85] Diastolic dysfunction is also common in T1DM,[86] especially in youth with microvascular disease (microalbuminuria or retinopathy),[87] with a prevalence as high as 25%[88] correlated with glucose control.[89] Cardiac mass has also been found to be higher in adolescents with T2DM compared with control subjects[90] with concomitant abnormalities with diastolic filling.[91] Clearly, adverse cardiac changes are occurring in young patients with both T1DM and T2DM.

Adverse vascular changes such as higher aortic thickness[92] and cIMT have been found in adolescents with T1DM compared with control subjects.[93–97] Factors associated with this higher cIMT include lower vitamin C levels[98] and longer duration of disease.[99,100] Adolescents with T2DM also demonstrate higher cIMT compared with healthy control subjects,[101,102] with diabetes mellitus duration[103] and glucose control playing a role.[104] Factors affecting the progression of cIMT in adolescents and young adults with diabetes mellitus include the number of receptors for advanced glycation end products,[105] HbA$_{1c}$,[106] and diabetes mellitus duration.[107] In adults, intensive diabetes mellitus treatment has slowed the progression of cIMT,[108] whereas in adolescents with T1DM (n=56), treatment with pentoxifylline, a hemorrheological agent available in Europe, led to regression of cIMT compared with placebo.[109]

Increased arterial stiffness, including lower abdominal aorta distensibility measured with ultrasound, was found in children with T1DM, although there was no association with diabetes mellitus duration or HbA$_{1c}$.[110] With the use of arterial tonometry, augmentation index, a measure that incorporates central arterial stiffness and wave reflections, and pulse-wave velocity, a measure of wave propagation, were found to be increased in children with T1DM.[93,94] Similar results were found in the larger SEARCH cardiovascular study (n=535), which found reduced brachial distensibility in youth with T1DM in addition to increased augmentation index and pulse-wave velocity.[111] Studies that found no increase in arterial stiffness in T1DM used nonstandard methods of assessing arterial stiffness that have not been validated in youth.[112,113] One large study of adolescents with T2DM (n=195) demonstrated increased arterial stiffness (lower brachial distensibility, higher augmentation index and pulse-wave velocity) in adolescents with T2DM compared with either lean or obese control subjects.[114] The only interventional study showed a trend for improvement in augmentation index with statin administration in youth with T1DM (n=51).[115]

Reduced brachial flow-mediated dilation has been found in very young (8.3±0.3 years) children with T1DM.[116] Endothelial dysfunction has been demonstrated in numerous studies in adolescents with T1DM.[96,117] Nonultrasound methods for assessing endothelial function, including peripheral arterial tonometry,[118,119] and laser flow Doppler studies[120] have demonstrated similar case-control differences. Poor endothelial function was associated with higher HbA$_{1c}$[121] and poor fitness level[122] but was not related to inflammation.[123] Endothelial dysfunction has also been found in youth with T2DM when measured by flow-mediated dilation[101] venous plethysmography.[124] Interventions including exercise[125] and intensive glucose control[126] improved endothelial function in young patients with T1DM. Collectively, these studies suggest significant cardiovascular compromise in youth with both T1DM and T2DM at a young age.

Peripheral neuropathy is another form of target organ damage found in young adults with diabetes mellitus.[127] Children with T1DM may already have abnormal nerve conduction at the time of diagnosis.[128] Heart rate variability analysis has emerged as a useful tool to assess autonomic tone, and studies in youth with diabetes mellitus have demonstrated a reduction in heart rate variability,[129] mostly with vagal withdrawal early[130] and sympathetic dysfunction later in the disease

process.[131] However, 1 large study (n=354) found overall heart rate variability reduction, suggesting a more advanced state of cardiac autonomic neuropathy.[132] Predictors of abnormal heart rate variability in children with T1DM included higher HbA_{1c}[132] and low PA.[133] The few small studies of neurological function conducted in youth with T2DM showed lower cognitive function,[134] peripheral neuropathy,[135] and lower heart rate variability compared with control subjects.[136] These early changes in neurological function have implications for future CVD because autonomic dysfunction measured in childhood predicts increased arterial stiffness 18 years later.[137]

Retinopathy is a microvascular complication of longstanding diabetes mellitus[138] that is associated with cognitive decline in adults.[139] Estimates of the incidence of retinopathy in youth with T1DM vary from 9%[140] to ≈15% per 100 person-years.[141,142] There are limited data in youth with adolescents with T2DM, but these data suggest similar retinal abnormalities are developing.[143,144] Factors influencing retinopathy in children with T1DM include vitamin D deficiency,[145] BP,[146] duration of disease,[147] and glucose control.[148,149] The prevalence appears to be declining in both children[150] and adults,[138] possibly related to more intensive treatment.[151]

In summary, target organ damage can be identified in adolescents with both T1DM and T2DM that is related to cardiovascular risk factors, duration of disease, and glucose control. Providers should follow the Pediatric Cardiovascular Risk Reduction Initiative recommendation on echocardiography in youth with hypertension that advocates echocardiography to rule out left ventricular hypertrophy before the initiation of antihypertensive therapy with the caveat that the goal for BP in diabetics is lower (the 90th percentile) compared with a nondiabetic population (the 95th percentile).[58] There is insufficient evidence to recommend other methods of imaging or testing for target organ damage for the prevention of CVD in youth with diabetes mellitus.

CVD Risk Factors

One approach to CVD risk reduction in diabetes mellitus uses the A, B, C approach. In addition to glucose control (HbA_{1c}, or A), blood pressure (BP or B) and cholesterol (C) management are emphasized.[56] Other modifiable CVD risk factors for people with diabetes mellitus include obesity, IR, inflammation, oxidative stress, kidney disease, and lifestyle factors such as smoking, diet, exercise, psychosocial stress, depression, and sleep. Nonmodifiable CVD risk factors include genetics, family history, diabetes mellitus duration, and racial/ethnic disparities.

Glucose Control

Glucose control is the cornerstone of diabetes mellitus management. The current ADA and ISPAD HbA_{1c} goals for children and adolescents are listed in Table 1.[55,61] These glucose goals have been extrapolated from adult studies that have shown that reduction of HbA_{1c} to ≈7% reduces microvascular complications (neuropathy, nephropathy, and retinopathy) in T1DM and T2DM.[34,151a] However, data on the relationship between HbA_{1c} and cardiovascular complications are weaker because large clinical trials and epidemiological cohort studies in adults have had conflicting results and long-term studies in children are lacking.

Type 1 Diabetes Mellitus

The DCCT and follow-up EDIC cohorts have shown that glycemic lowering, even for a few years, reduces the future rate of myocardial infarction, stroke, and CVD death.[21,34,153] Several large, prospective, observational cohort studies, including the EDC,[154] the EURODIAB Prospective Complications Study (EURODIAB),[155] and the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR),[156] have failed to demonstrate similar results. Possible explanations for the discrepancies between studies are that the DCCT/EDIC cohort initiated intensive insulin therapy early in a population with a relatively short duration of diabetes mellitus, the cohort had a low prevalence of IR and renal disease (both strong predictors of coronary artery disease), and the intensive insulin treatment arm achieved a remarkably low mean HbA_{1c} of 7.4%.[20] Thus, the relationship between lowering of HbA_{1c} and reduction of cardiovascular events likely exists but only in a cohort at low risk for coronary artery disease with a short duration of diabetes mellitus when tight glucose control is achieved early. Such an interpretation emphasizes the importance of glucose control in youth.

Data addressing cardiovascular events are currently unavailable in the pediatric age group. Thus, studies evaluating the relationship between HbA_{1c} and CVD outcomes in youth have relied on noninvasive imaging modalities to assess the early vasculature changes.[157] In adolescents (mean age, 18.1±3.1 years), Krantz et al[158] found no relationship between HbA_{1c} and cIMT. Similarly, Haller et al[159] also found no association between HbA_{1c} and augmentation index measured by radial tonometry (age range, 10–18 years). Wadwa et al[160] noted a univariate association between HbA_{1c} and pulse-wave velocity but not after adjusting for other risk factors. These cross-sectional data in youth with T1DM emphasize that longitudinal studies are needed because the effects of glucose control on CVD outcomes did not manifest until 17 years of follow-up in the DCCT/EDIC study.

Type 2 Diabetes Mellitus

Similar to T1DM, data from the UK Prospective Diabetes Study (UKPDS)[151a,161] and its 10-year cohort follow-up[163,164] suggest that intensive glucose control may be of greater CVD benefit when initiated early in T2DM. Conflicting results have been seen in more recent clinical trials in older adults with more advanced CVD.[165–167] In fact, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which aimed to achieve an HbA_{1c} of <6% in adults with a known cardiovascular event or major CVD risk factor, was halted because of the finding of increased mortality in the intensive treatment arm.[168]

Only a few studies in adolescents with T2DM have evaluated the association between HbA_{1c} and early vascular changes. Wadwa et al[160] studied 60 adolescents (mean age, 17.4±2.7 years) with a median duration of diabetes mellitus of 3.1 years (range, 2.1–4.5 years) and found no relationship between HbA_{1c} and arterial stiffness. In contrast, using cIMT, Shah et al[169] demonstrated an independent association with HbA_{1c} in 129 adolescents (mean age, 18.9±3.2 years) such that each 1% increase in HbA_{1c} was associated with a 30% increase in the odds for a thicker carotid artery. Similarly, Kotb et al[103] found a univariate association between HbA_{1c} and cIMT in youth 12 to 19 years of age. These cross-sectional

studies in T2DM youth suggest that glucose control is associated with increased arterial thickness but not stiffness.

In summary, it is important to note that although the data from older adults suggest a minimal effect of intensive HbA$_{1c}$ lowering on CVD, this should not be extrapolated to imply no future benefit in pediatric diabetes mellitus. Instead, what long-term follow-up of the DCCT/EDIC and UKPDS cohorts suggests is that improved glucose control, when initiated early in young people, leads to a reduction in cardiovascular events. This is of crucial importance in the pediatric population, in which improved glucose control has the potential to alter future CVD risk. Additionally, given the known benefits of lowering HbA$_{1c}$ on microvascular complications, clinicians should emphasize the long-term benefits of tight glucose control in children and adolescents with diabetes mellitus.

Blood Pressure

The prevalence of clinic hypertension in youth with T1DM (4%–7%)[170,171] and T2DM (25%–40%)[68,172,173] is higher than in healthy children. Abnormal ambulatory BP patterns[174,175] such as reduced nocturnal dipping[176] may also be identified. Higher BP levels predispose to the development of microalbuminuria,[177] nephropathy,[178] retinopathy,[146] and carotid thickening.[179,180] The determinants of BP levels in children with diabetes mellitus include poor diet,[181] adiposity,[182,183] diabetes mellitus–related autonomic imbalance,[130,184] and poor glucose control.[185,186]

Adult guidelines set the goal for BP in people with diabetes mellitus to ≤130/80 mm Hg on the basis of longitudinal studies with hard cardiovascular events as outcome.[77] Lowering BP further may improve target organ measures (cIMT, left ventricular mass, proteinuria),[187,188] but the risk of a drop in diastolic BP to <60 mm Hg,[189] a level that may impair coronary filling, has led the ADA to suggest avoiding hypotension.[56] No pediatric longitudinal studies with hard cardiovascular events are available; however, evidence for target organ damage in youth with diabetes mellitus[102,114,190] led to the recognition that children with either T1DM or T2DM are at elevated risk of developing atherosclerotic CVD before 30 years of age.[58] Therefore, reducing BP to the ≤90th percentile for age, sex, and height or ≤120/80 mm Hg at any age was recommended.[58] Although these recommendations were based on inferences gained from cross-sectional studies, observational studies, and adult data (grade D, expert opinion), the American Academy of Pediatrics endorses the goal of BP ≤90th percentile in pediatric diabetes mellitus.[57] In summary, the recent Pediatric Cardiovascular Risk Reduction Initiative recommendation for screening for and treatment of hypertension in youth with diabetes mellitus provides comprehensive guidance.[58]

Cholesterol

Elevated LDL-c is firmly established by genetic, epidemiological, and animal studies as a major contributing risk factor to CVD.[191–197] Therefore, LDL-c is the primary target for lipid health in children and adolescents.[198] In the SEARCH study, the prevalence of an elevated LDL-c (>130 mg/dL) is 15% and 24% in youth with T1DM and T2DM, respectively.[69] LDL-c lowering reduces cardiovascular events in adults with T2DM[199] and improves subclinical atherosclerosis in children with familial hypercholesterolemia.[200,201] Collectively, these data suggest that LDL-c lowering may attenuate the risk for atherosclerosis in youth with diabetes mellitus.

Type 1 Diabetes Mellitus

Limited longitudinal prospective studies are available on cholesterol management in youth with diabetes mellitus. For T1DM, longitudinal prospective studies of at least 2 years' duration and involving between 46 and 1100 patients demonstrate that worse glucose control (increased HbA$_{1c}$) is associated with increased LDL-c (or the highly correlated non–high-density lipoprotein [HDL] cholesterol)[202–207] and demonstrate an increase in LDL-c with increasing body mass index (BMI) or BMI z score.[203,204,206] In addition, a large cross-sectional study of ≈29 000 German and Austrian patients with T1DM demonstrated strong associations between LDL-c and HbA$_{1c}$ and between LDL-c and BMI.[208] From these data, it is clear that lower LDL-c levels can be achieved by improved glucose control and reduced BMI in addition to a healthy diet.

Type 2 Diabetes Mellitus

Few studies address hyperlipidemias in pediatric T2DM. A longitudinal study demonstrated increased LDL-c with worse glucose control,[209] and a cross-sectional study reported higher LDL-c levels in patients with higher mean HbA$_{1c}$ and BMI z scores.[28] Data from the TODAY study suggest that behavioral intervention and glucose control will not be sufficient to achieve lipid goals in adolescents with T2DM.[210] Importantly, in T2DM and potentially T1DM, the high levels of insulin that result from IR cause hyperlipidemia by selectively stimulating lipoprotein production via the liver transcription factor sterol regulatory element binding protein 1c.[211] Therefore, therapies that reduce IR (including PA, weight reduction, and metformin) can reduce hyperlipidemia. Reducing IR will also improve HDL cholesterol and triglyceride levels, which frequently are abnormal in T2DM.[69]

Treatment

The questions remain whether the LDL-c lowering achieved with nonpharmacological interventions is sufficient to prevent atherosclerosis or to achieve lipid goals,[202,206] at precisely what age LDL-c reduction should begin,[212] and what the ideal LDL-c treatment goal should be. The association of HbA$_{1c}$ and BMI change with lipids was positive but may be insufficient to achieve lipid goals on the basis of observational data from the SEARCH study in T1DM youth,[206] similar to the TODAY data in T2DM youth.[210] Although statins are considered safe and well tolerated in adults, long-term safety studies that follow up children into adulthood are lacking. The AHA statement on drug therapy cautions that statin use in adolescence needs to be studied further to determine the impact on psychological and intellectual development.[5] Animal studies raise concerns about potential untoward effects of statins on the rapidly developing central nervous system (eg, impaired myelin formation).[213,214] However, many statins do not cross the blood-brain barrier, data in adults suggest no harmful central nervous system effects,[215–217] and randomized, placebo-controlled studies of statins in children with familial hyperlipidemia have not demonstrated adverse effects in growth or development.[8] It is important to be aware of the teratogenicity of statins when prescribing

them for female patients of childbearing age.[5] Some adult studies have shown regression of coronary atherosclerosis assessed by angioplasty or carotid ultrasound. Therefore, it may be possible to reduce existing atherosclerotic disease with intensive lipid-lowering therapy at an older age.[218,219] The pros and cons of pharmacological treatment of dyslipidemia in adolescents with diabetes mellitus are reviewed elsewhere.[212,220]

In summary, LDL-c levels >130 mg/dL in T1DM and T2DM warrant interventions to reduce LDL-c levels by improving glucose control, decreasing IR (BMI reduction, healthy diet, and increased PA), and, in postpubertal children, considering the addition of a pharmacological agent.

Obesity

Type 1 Diabetes Mellitus

Compared with those with T2DM, fewer children and adolescents with T1DM are overweight or obese. However, in the SEARCH study, ≈22% of the children and adolescents with T1DM were overweight, and this percentage was higher than youth without diabetes mellitus in the National Health and Nutrition Examination Survey (NHANES) cohort (≈16%).[221] The prevalence of obesity in youth with T1DM in this study was ≈12.6%. Emerging evidence suggests that higher doses of insulin used to improve glucose control are associated with greater increases in BMI over time.[222]

Drawing from the adult literature, it is clear that intensive treatment aimed at improving glucose control is associated with weight gain and worsening of the cardiovascular risk factor profile among patients with T1DM. Data from the DCCT demonstrated that subjects in the top quartile of weight gain had the highest BMI, waist-to-hip ratio, BP, and proatherogenic lipoprotein level.[223] The only distinguishing factor at baseline between these patients and those in the lower quartiles of weight gain was higher HbA$_{1c}$, suggesting that the intensity of treatment was likely responsible for the increase in central adiposity and deterioration of the CVD risk factors. Moreover, in the EDIC follow-up study, those who were in the top quartile of BMI change in the intensively treated arm had greater cIMT and tended to have higher coronary artery calcification scores compared with those in the lower BMI change quartiles.[224] Together, these data suggest that more intensive glucose control, likely achieved with higher insulin use, is associated with progressive worsening of CVD risk factors and subclinical atherosclerosis among those in the highest quartile of BMI increase.

Type 2 Diabetes Mellitus

Results from the SEARCH study suggest that ≈80% of youth with T2DM are obese (≈10% are overweight).[221] Obesity is a pathogenetic factor contributing to the development of T2DM among children and adolescents, likely through its association with IR, one of the primary pathophysiological processes underlying the disease. Therefore, in addition to achieving optimal glucose control, managing obesity should be a primary consideration in the treatment strategy for pediatric T2DM. Unfortunately, many drugs used to treat hyperglycemia are associated with weight gain (insulin, thiazolidinediones, and sulfonylureas). Indeed, treatment with rosiglitazone in the TODAY study was associated with increasing BMI and body fat.[60] Results of the TODAY study further suggest that weight loss is extremely difficult for pediatric patients with T2DM. Despite relatively intensive lifestyle modification/behavioral counseling and metformin offered throughout the study, mean BMI and body fat increased in all 3 treatment arms.[60]

Ideally, medications used to treat pediatric T2DM should be associated with weight loss or at least should have a weight-neutral effect. According to recent guidelines from the American Academy of Pediatrics,[225] metformin should be the first-line therapy for the treatment of pediatric T2DM. In general, metformin is associated with modest weight loss. Three randomized, placebo-controlled trials conducted in obese youth without diabetes mellitus reported a BMI reduction of ≈3% over a treatment period of 6 to 12 months.[226–228] Neither glucagon-like peptide-1 receptor agonists nor dipeptidyl peptidase-4 inhibitors are currently approved by the US Food and Drug Administration for the treatment of T2DM in children and adolescents. However, if the safety and efficacy of these drug classes are established and US Food and Drug Administration approval is obtained, these medications may be an attractive option because glucagon-like peptide-1 receptor agonists are associated with weight loss and dipeptidyl peptidase-4 inhibitors appear to be weight neutral, although safety concerns about long-term treatment exist that are based on recent autopsy studies.[229] Two relatively small clinical trials have demonstrated that exenatide, a glucagon-like peptide-1 receptor agonist, reduces BMI by ≈3% to 4% in severely obese adolescents without diabetes mellitus.[230,231]

Although typically reserved for severely obese adolescents with significant comorbidities, bariatric surgery has been shown to be far superior to lifestyle modification therapy or pharmacotherapy in terms of BMI reduction[232–234] and may be an effective treatment option for severely obese teens with T2DM. Beyond weight reduction, improved glucose control appears to be an important benefit of bariatric surgery among patients with T2DM. Indeed, a recent study in adults with T2DM demonstrated that compared with those treated with medical management alone, patients who underwent Roux-en-Y gastric bypass required on average 3 fewer medications for glucose control.[235] In youth with T2DM, Roux-en-Y gastric bypass led to remission of the T2DM in 10 of the 11 participants, with significant improvements in BMI (−34%), fasting blood glucose (−41%), fasting insulin concentrations (−81%), HbA$_{1c}$ levels (7.3%–5.6%), IR, serum lipid levels, and BP.[236] However, much more information about the long-term safety and efficacy of surgical management is be needed before recommendations can be offered on the use of bariatric surgery for the treatment of obesity and T2DM among adolescents.

In summary, obesity increases CVD risk in both T1DM and T2DM, and a direct parallel can be drawn between T2DM and T1DM in terms of treatment approaches aimed at reducing obesity (T2DM) and preventing obesity (T1DM).

Insulin Resistance

IR predicts cardiovascular morbidity and mortality in the metabolic syndrome and T2DM.[237–239] IR is best measured by the hyperinsulinemic-euglycemic clamp using the glucose disposal rate (GDR), especially in diabetes mellitus, in which β-cell dysfunction disrupts estimates based on fasting insulin. However, clamp studies are difficult to perform. Therefore, non–insulin-based estimates were recently created with the use of surrogate

clinical measures.[240,241] The presence of pathological IR in youth is concerning because early onset translates to long exposure of the cardiovascular system to its negative effects.

Type 1 Diabetes Mellitus

IR is increasingly recognized as a key factor in T1DM.[84] Normal-weight adolescents with T1DM have significantly lower GDR than control subjects[84,242] matched for BMI, pubertal stage, and activity level[84] and were as insulin resistant as obese nondiabetic youth.[84] Importantly, IR (low GDR) is associated with a more atherogenic fasting lipid profile and lipoprotein subfraction cholesterol distribution and decreased cardiopulmonary fitness and vascular reactivity.[84,243–245] Although long-term data linking IR in T1DM youth to negative long-term cardiovascular outcomes in T1DM adults are lacking, IR correlates with coronary artery calcification,[246] coronary artery disease, and actual cardiovascular events.[154,247] These data argue that IR in T1DM has effects on the cardiovascular system similar to those seen in T2DM.

Despite the significant IR reported in T1DM, the phenotype of IR is unique in that individuals with T1DM typically lack the metabolic syndrome features characteristic of T2DM. For example, compared with individuals with T2DM or obese and normal-weight control subjects, youth with T1DM had lower intrahepatic, visceral, and intramyocelluar fat, BP, and triglycerides and higher HDL and adiponectin than expected.[84,244,245] Also unexpectedly, intra-abdominal fat volume did not correlate with IR in adult women with T1DM.[248] Thus, the mechanisms of IR likely differ between T1DM and T2DM, requiring further research to customize treatment strategies. Furthermore, obesity is now common in youth with T1DM (40% of adolescents with T1DM in the large multicenter T1D Exchange Network were overweight or obese),[35] likely further worsening IR and CVD, because obesity in adults with T1DM predicts coronary artery calcification progression, independently of dyslipidemia, hypertension, and inflammation.[249] Accordingly, direct prevention and treatment of IR are now priorities in T1DM research.

Type 2 Diabetes Mellitus

IR is present from the early stages of T2DM. Adolescents with T2DM are more insulin resistant than obese adolescents matched for BMI, Tanner stage, and PA level.[250] Urbina et al[251] found that arterial stiffness, as measured by brachial artery distensibility and pulse-wave velocity, was associated with HOMA (homeostasis model assessment)-assessed IR in adolescents and young adults with T2DM, although not independently of age, sex, BMI, and BP. Similarly, Kotb et al[103] found that cIMT was higher in adolescents with T2DM than in control subjects and correlated with HOMA-assessed IR. Nadeau et al[250] reported reduced cardiopulmonary fitness in adolescents with T2DM compared with lean and obese adolescents, and this reduction in $\dot{V}o_2$ peak was strongly and independently correlated with GDR. Furthermore, Cerutti et al[252] determined that adolescents with T2DM had reduced vagal but increased sympathetic indexes, indicating autonomic dysfunction, which correlated with oral glucose tolerance test–derived IR. Perez-Mendez et al[253] found that HDL cholesterol size distribution was shifted toward smaller particles in pediatric T2DM

patients and that HOMA-derived IR was the main factor associated with these HDL size abnormalities.

Given the association between IR and CVD risk factors in T2DM, treatment aimed at improving IR is critical. Metformin (HOMA),[254] thiazolidinediones (GDR),[60,255,256] structured exercise independent of weight change (GDR),[257,258] and weight loss (GDR and hepatic IR)[259,260] are all reported to improve IR in youth with T2DM or obesity. In particular, the drastic weight loss seen with gastric bypass has resulted in T2DM remission and improvements in IR (fasting insulin, ratio of triglycerides to HDL), β-cell function, and cardiovascular risk factors in adolescents and adults with T2DM.[236,261] In addition, IR (assessed by steady-state plasma glucose) was the sole independent predictor of endothelial dysfunction in adults with T2DM as assessed by flow-mediated dilation, and pioglitazone treatment improved endothelial function, which significantly correlated with improved IR.[262]

In summary, mechanisms underlying IR in T1DM and T2DM may differ, and new methods to improve IR in pediatric diabetes mellitus are critically needed.

Inflammation

Type 1 Diabetes Mellitus

Although inflammation has been implicated in the pathogenesis of T1DM,[263,264] many studies have sought to examine whether inflammation is associated with CVD risk factors. In the SEARCH study, children and adolescents with T1DM had higher levels of interleukin-6 and fibrinogen compared with normal-weight subjects.[265] In addition, C-reactive protein was higher in patients with diabetes mellitus in the top 3 quartiles of HbA$_{1c}$. Other studies have reported that T1DM is associated with elevated C-reactive protein[266] and monocyte chemoattractant protein-1.[267] Acute hyperglycemia, poorer glucose control, and dysregulated adipocyte function may be some of the mechanisms involved in the higher levels of inflammation observed in pediatric T1DM.[244,245,268]

Type 2 Diabetes Mellitus

Adolescents with T2DM had higher levels of C-reactive protein and interleukin-6 compared with obese adolescents without diabetes mellitus and normal-weight controls.[250] Two studies demonstrated that children and adolescents with T2DM had higher levels of C-reactive protein compared with normal-weight control subjects but that levels were not significantly higher than those among obese youth without diabetes mellitus.[102,114] In a study of obese First Nation youth with and without T2DM, there was no difference between groups for tumor necrosis factor-α or C-reactive protein; however, interleukin-6 levels were higher in those with T2DM compared with those without diabetes mellitus.[271]

From current evidence, it appears that inflammation is elevated in the context of pediatric T2DM but that levels are not consistently higher than those found in obese youth without diabetes mellitus. It will be important for future studies to evaluate the impact of various diabetes mellitus treatments on inflammatory cytokines. Indeed, studies in adults have demonstrated that thiazolidinediones, metformin, and glucagon-like peptide-1 receptor agonists can reduce inflammation.[272–276]

Oxidative Stress

Type 1 Diabetes Mellitus

Oxidative stress is thought to be a primary mechanism involved in atherogenesis. Within the context of diabetes mellitus, chronic hyperglycemia and acute hyperglycemia produce free radicals and thereby increase levels of oxidative stress.[277] Most[278–285] but not all[286] studies report that oxidative stress levels are higher in youth with T1DM compared with healthy control subjects. Consistent with the hypothesis that uncontrolled hyperglycemia is one of the primary mechanisms responsible for oxidative stress in diabetes mellitus, multiple studies have suggested that levels of oxidative stress tend to be higher at diagnosis and subsequently decrease over time as glucose control is established.[282–285,287] Evidence suggests that oxidative stress in pediatric T1DM is associated with inflammation, endothelial activation, and other early signs of vascular dysfunction.[98,288,289,291] Although intervention studies are few, 1 study reported that vitamin E supplementation reduced levels of oxidative stress among children with T1DM.[292]

Type 2 Diabetes Mellitus

Despite the important implications in relation to CVD risk, little is known about oxidative stress in pediatric T2DM. One study compared levels of antioxidants and markers of oxidative stress among 3 groups: adolescents with T2DM, obese control subjects without diabetes mellitus, and normal-weight control subjects.[271] Although antioxidant status did not differ among the groups, levels of oxidized LDL-c were higher in those with T2DM compared with the normal-weight control subjects but were not different from levels in the obese control subjects without diabetes mellitus, suggesting that oxidative stress was associated with obesity and not diabetes mellitus per se.

Kidney Function

Renal disease in youth with diabetes mellitus differs significantly between patients with T1DM and T2DM. Development of diabetic nephropathy in T1DM classically takes 10 to 15 or more years to manifest clinically, although clinically silent changes such as glomerular hyperfiltration and ultrastructural abnormalities may be present for years before overt nephropathy can be demonstrated. On the other hand, renal manifestations can almost always be demonstrated at the time of diagnosis in patients with T2DM, which reflects the years of obesity-related metabolic and hemodynamic abnormalities these patients have experienced before becoming symptomatic from their diabetes mellitus.[293]

Type 1 Diabetes Mellitus

In a group of children enrolled in the Oxford Regional Prospective Study,[294] glomerular hyperfiltration was associated with both the advent of puberty and the development of microalbuminuria independently of glucose control. However, in a study of young adults from the First Joslin Kidney Study,[295] renal hyperfiltration did not appear to affect the development of microalbuminuria over 15 years of follow-up. Most recently, a study conducted in Finnish adults demonstrated that the incidence of hyperfiltration was similar in adults with T1DM compared with the general population and that patients with T1DM with higher estimated glomerular filtration rate were not more likely to develop microalbuminuria than those with normal glomerular filtration rate.[296] Taken together, these results suggest that hyperfiltration may be more important at younger ages. Thus, children with T1DM who manifest hyperfiltration may be at increased risk of developing microalbuminuria, whereas this may not be the case for adults.

On the other hand, renal structural changes develop early in T1DM, even in children, and are correlated with the development of microalbuminuria and systemic hypertension.[297] Renal biopsies performed in patients aged 10 to 40 years of age enrolled in the International Diabetic Nephropathy Study[298] showed that thickening of the glomerular basement membrane and increased mesangial matrix could be demonstrated after just 2 to 8 years of T1DM and that these abnormalities correlated with diastolic BP and duration of diabetes mellitus. Follow-up of this cohort demonstrated a correlation between the basement membrane changes and microalbuminuria, as well as a potential association with increased glomerular filtration rate.[299] A more recent biopsy study[300] confirmed that thicker glomerular basement membranes, poorer glucose control, and higher BP were significant predictors of microalbuminuria on long-term follow-up. Noninvasive markers of renal structural damage in T1DM that could help determine the optimal time to initiate renoprotective treatment are still needed at this time.

Type 2 Diabetes Mellitus

Several studies have demonstrated a 2- to 3-fold higher prevalence of microalbuminuria and macroalbuminuria in youth with T2DM compared with youth with T1DM,[301,302] as well as other features of diabetic nephropathy such as hypertension. In the TODAY study,[172] ≈13% of youth had microalbuminuria; even more alarmingly, nearly 40% had elevated BP. In Pima Indian youth with T2DM, microalbuminuria was common, affecting 18.5%, and predicted the development of macroalbuminuria.[303] However, in another study conducted in First Nation youth with T2DM,[304] ≈50% had intermittent microalbuminuria; within a subgroup of patients with persistent macroalbuminuria who had renal biopsies performed, most had evidence of immune complex deposition, suggesting that microalbuminuria in pediatric patients with T2DM is not always purely diabetes mellitus related.

In adults, it is well established that the metabolic abnormalities characteristic of obesity precede the development of symptomatic T2DM.[293] A similar pathophysiology likely precedes the development of T2DM in pediatric patients. Numerous studies have shown that abnormal BP can be demonstrated early in the course of T2DM in children. Elevated BP is common in obese adolescents,[305] and abnormalities of ambulatory BP are associated with abnormal metabolic factors.[306] In both the TODAY[172] and the SEARCH[68] studies, hypertension was common and was more frequent with increasing BMI. In another study using ambulatory BP monitoring,[307] abnormal BP patterns and microalbuminuria were both common in minority youth with relatively recently diagnosed T2DM. Thus, it appears that in T2DM long-standing metabolic abnormalities associated with obesity result in the development of both renal and cardiovascular manifestations suggestive of early diabetic nephropathy, even in adolescents.

There is controversy as to whether microalbuminuria is solely a marker of kidney disease. Microalbuminuria can remit and progress and may represent vascular damage in some patients or renal damage in others. Youth with diabetes mellitus are clearly a high-risk population who should be screened for renal disease and treated aggressively to prevent future CVD.

Smoking

In a study of Egyptian adolescents with T1DM, 50% of cigarette smokers had evidence of coronary artery calcification compared with 9.1% of nonsmokers (*P*<0.001).[308] Cigarette smoking in youth with T1DM also contributes to CVD risk through worsening glucose control, lipid profile, and endothelial function.[309] In the most comprehensive study of tobacco use among youth with diabetes mellitus, the SEARCH study found that the prevalence of cigarette smoking increased with age.[310] Among youth with T1DM who were 10 to 14, 15 to 19, and ≥ 20 years of age, the prevalence of smoking was 2.7%, 17.1%, and 34.0%, respectively.[310] In youth with T2DM who were 10 to 14, 15 to 19, and ≥20 years of age, the prevalence was 5.5%, 16.4%, and 40.3%, respectively.[310] Smoking among youth with either T1DM or T2DM was more common among those living in households with family annual incomes of ≤$50 000, suggesting the impact of socioeconomic status on the adaptation of smoking habits. Past and current smokers with T1DM had a higher prevalence of high triglyceride levels, high LDL levels, low HDL, and physical inactivity compared with the nonsmokers.[310] Similar associations were noted for youth with T2DM; however, likely because of the small sample size and number of cigarette smokers, the results did not reach statistical significance with the exception of high triglyceride levels. Smoking appears to increase CVD risk directly (eg, worsening endothelial function) and through its association with behavioral risk factors (eg, physical inactivity). The SEARCH study noted that <50% of youth 10 to 14 years of age reported being counseled by their healthcare provider about starting or stopping cigarette smoking.[310] Despite the health consequences associated with smoking, there appear to be no intervention trials in youth with diabetes mellitus designed to promote the avoidance of smoking. Strategies used by healthcare providers may include office-based screening and counseling methods, strategies to promote the use of these methods, and resources to help maintain cigarette avoidance between office visits.[312]

Diet

Numerous studies suggest that nutrition influences CVD risk.[193,313,314] Medical nutrition therapy guidelines have been shown to improve CVD risk factors in adults with diabetes mellitus[314,316]; however, studies evaluating the influence of specific dietary macronutrient content and eating patterns have yielded inconclusive results.[317] Observational and comparative studies among youth suggest that CVD risk may be influenced by diet composition, family cohesion, eating behaviors, and knowledge of and adherence to dietary recommendations.

The ADA guidelines for medical nutrition therapy do not recommend a specific distribution of macronutrient content in the diet. These guidelines are highly individualized, with recommendations that the combination of carbohydrates, protein, and fat be adjusted to meet glucose, BP, and lipid goals.[56] Additionally, these guidelines recommend that the intake of saturated fat should be <7% of total calories.[56] ISPAD recommends that the total daily distribution of energy intake in youth with diabetes mellitus includes a diet of carbohydrate (50%–55%), fats (30%–35%), and protein (10%–15%), with saturated fats and *trans* fatty acids making up <10% of total fat calories. These guidelines also recommend that caloric intake should be sufficient to achieve and maintain optimal growth and body weight.[318] In general, the overall recommendations of the ADA and ISPAD are consistent with recommendations in the *Dietary Guidelines for Americans,*[319] which emphasize incorporation of fruits, vegetables, whole grains, and low-fat food choices.

Type 1 Diabetes Mellitus

With the exception of 1 study,[320] the dietary intake of youth with T1DM failed to meet nutritional recommendations, with fruit, vegetable, and whole grain intake below and fat intake above recommended quantities.[321–326] Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet, which prescribes a high proportion of fruits and vegetables, was associated with lower BP, better ratio of LDL to HDL, and lower HbA$_{1c}$ in youth with T1DM.[327,328] Sugar-sweetened beverage consumption and diet beverage consumption have been associated with adverse lipid, BP, and HbA$_{1c}$ levels, which may be a marker for other concurrent unhealthy lifestyle behaviors (eg, unhealthy diet, sedentary lifestyle, and increased screen time).[329] Dietary knowledge, adherence, and family involvement may play a role in diet quality and improved glucose. Monitoring of carbohydrate intake through carbohydrate counting is an important strategy to improve glucose control.[330] However, reduction of carbohydrate may contribute to increased fat intake as diabetes mellitus management (to improve glucose control) and may have negative effects on cardiovascular health.[331,332] Youth with T1DM have documented higher fat intakes that are positively associated with HbA$_{1c}$ levels.[333]

Disturbed eating behaviors are common among youth with T1DM. These behaviors tend to cluster around increased dietary restraint (conscious restriction of food intake), binge eating,[334] and poor diet quality.[335,336] Many adolescents report weight and body shape concerns, unhealthy weight control behaviors, diminished self-worth, and depression.[337–339] Disturbed eating behaviors are more prevalent with increased BMI[335,336] and with the perception of being overweight.[340] Disturbed eating behaviors, coupled with unhealthy weight control behaviors, have been associated with adverse glucose control.[338,341] Up to 50.4% of male and female adolescents with T1DM reported using weight control behaviors.[338] Insulin omission and insulin underdosing are the most serious weight control behaviors reported. In an 11-year longitudinal study of adult women, insulin restriction was found to be significantly associated with increased morbidity and mortality with a 3.2-times increased risk of death after controlling for age, BMI, and HbA$_{1c}$.[342]

Type 2 Diabetes Mellitus

Youth with T2DM also fail to meet nutritional recommendations. The baseline dietary assessments from the TODAY study revealed that only 1% of youth met the ADA recommendation

for <7% intake of saturated fat.[343] Adherence to the DASH diet was associated with improved LDL particle density and BMI in youth with T2DM.[327] No studies examining micronutrient intake in youth with T2DM were found.

One study examined dietary adherence among youth with T2DM using a telephone survey of patients from 1 diabetes mellitus clinic. The participants reported that the greatest difficulty in diabetes mellitus self-management was adhering to dietary recommendations. Most subjects reported overeating at least once weekly, drinking sugar-sweetened beverages at least once daily, and eating fast food >4 times per month.[344] Consistent with studies in T1DM youth, disturbed eating behaviors were common and associated with being overweight in both male and female subjects and with poor glucose control in female subjects.[340] In a telephone survey, dietary recommendations were reported to be challenging to achieve, and the participants reported that they frequently overate, drank sugar-sweetened beverages, and ate fast food. The greatest reported challenges to healthy eating were feeling stressed or sad, having food cravings, and eating outside of the home.[344]

In summary, adherence to carbohydrate counting and the DASH diet has been associated with improved CVD markers. High fat intake is a consistent dietary pattern that requires additional strategies to minimize. Youth with T1DM and T2DM who exhibit disturbed eating behaviors or body weight dissatisfaction, are overweight, or perceive themselves to be overweight are at risk for participation in unhealthy weight control behaviors and poor glucose control, which can lead to vascular complications.

Exercise

Youth with T1DM and T2DM appear to be more sedentary and less fit than nondiabetic youth.[344a–351] PA is not associated with glycemic outcomes in some large studies[352,353] but was among the factors most strongly associated with HbA_{1c} in the Diabetes Patientien Verlaufsdokumentation (DPV) study.[354] In contrast, physical fitness among youth with T1DM and T2DM is more consistently associated with lower HbA_{1c}.[346,355–357] Small studies have reported that aerobic and strength training yields increased fitness and decreased daily insulin dosage compared with normal daily activities[358] and that greater PA improves fitness without changing HbA_{1c}.[359] In a large study of overweight/obese and sedentary children, 3 months of aerobic training yielded dose-dependent improvements in IR and adiposity compared with usual PA.[360]

Psychosocial Stress

Stressful life events among adolescents with diabetes mellitus are associated with negative emotional reactions and worse diabetes mellitus control, in part as a result of poor self-care.[361] Good family relations may lower HbA_{1c} among girls.[361] Surprisingly, diabetes mellitus and its management were not a common theme among stressors reported by youth with T1DM.[362] Family stress may be associated with higher HbA_{1c},[363] perhaps mediated by anxiety in the child.[364] Adolescents who perceive their parents as more controlling report greater depressive symptoms, whereas those who perceive their parents as accepting have lesser depressive symptoms.[365] General stress among parents is associated with more depressive symptoms and poorer self-care, glucose control, and blood glucose monitoring,[366] whereas diabetes mellitus–specific stress among parents is associated with more frequent blood glucose monitoring and better child-reported self-care.[366]

Depression

Depression among youth with diabetes mellitus has been associated with poorer diabetes mellitus control, increased complications, and greater service use.[367] A meta-analysis of 22 case-control studies found that psychological problems, including depressive symptoms, were more likely among children with versus without diabetes mellitus,[368] although exceptions exist.[369,370] In a large study of youth with T1DM, 17% had significant depressive symptoms, half of whom did not discuss these symptoms with their pediatrician or nurse.[371] Some depressive symptoms overlap with diabetes mellitus–related physical symptoms; however, youth with diabetes mellitus endorse all depressive symptoms more frequently than youth without diabetes mellitus.[372]

Depressive symptoms may be associated with poorer blood glucose monitoring[373,374] and poorer diabetes mellitus control.[361,375–377] Depressive symptoms are also associated with impaired hypoglycemia awareness[378] and may independently predict proteinuria.[379] A study of 276 adolescents with diabetes mellitus found that blood glucose monitoring frequency explains 38% of the association between HbA_{1c} and depressive symptoms (ie, with depressive symptoms, blood glucose monitoring decreases and HbA_{1c} increases).[380] A large study of adolescents at risk for T2DM by virtue of high BMI together with a family history of diabetes mellitus found that depressive symptom severity was directly associated with BMI and fasting insulin levels.[381] However, other studies have not found associations between emotional/behavioral problems and metabolic control.[382] Screening for depression is advised for adolescents overall,[383] and this may be especially important for those with diabetes mellitus.

Sleep

Alterations in sleep (time, disruption, architecture, and quality) are associated with neuroendocrine changes in appetite,[384] sympathetic nervous system arousal,[385] and metabolic dysregulation.[385,386] In the general adult population and in healthy children and adolescents, sleep alterations may adversely influence glucose regulation,[385] C-reactive protein,[387] and lipids[388] and increase the risk for hypertension, T2DM, heart attack, and stroke.[389,390] Reports of reduced sleep times of up to 64%[391] have been documented for children and adolescents with diabetes mellitus who confront additional challenges with sleep as a result of diabetes mellitus management[392,393] that may further disrupt sleep and add to adverse cardiovascular outcomes.

In adults with T1DM, short sleep duration was associated with reduced insulin sensitivity,[394] increased HbA_{1c},[395] and a greater prevalence of nondipping BP patterns.[395,396] Additionally, 2 polysomnographic studies revealed that those with T1DM spent more sleep time in lighter stages of sleep (stages 1 and 2) and less time in restorative slow-wave sleep (stage 3) compared with healthy control subjects.[397,398] One observational study compared sleep stages in youth with T1DM and age-, sex-, and BMI-matched control subjects.[399] Consistent with adult studies, the diabetic cohort spent

significantly more time in stage 2 and less time in stage 3 sleep than the control group. Within the diabetic cohort, those who spent the most time in stage 2 sleep also had higher daily glucose and HbA$_{1c}$ levels, suggesting metabolic dysregulation with lighter sleep.[399] The association of hypoglycemia with depth of sleep has been conflicting[400,401]; however, fluctuations in glucose levels (≥25 mg·dL^{-1}·h^{-1}), even when the blood glucose level remained within normal ranges, have been associated with sleep disruption.[400] Because glycemic variability is associated with cardiovascular risk, the potential impact of nocturnal glucose variability on cardiovascular health requires further research. Obstructive sleep apnea, associated with obesity in children, may augment CVD risk in those affected.[402]

Nonmodifiable Risk Factors

Genetics and Family History

Nonmodifiable CVD risk factors for both T1DM and T2DM include genetics, family history, and diabetes mellitus duration. There have been numerous investigations into genetic risk factors for CVD in general[403] and in T1DM specifically.[404,405] Systems under investigation for potential increased genetic risk for CVD in T1DM were reviewed by Orchard et al[20] and include polymorphisms in the receptors for advanced glycation end products, angiotensin-converting enzyme, neuropeptide Y, hepatic lipase, apolipoprotein A-IV, von Willebrand factor, haptoglobin, nitric oxide synthase, and adiponectin, among others.[20,406] Similarly, genetic variation in *CALPN10*, *FABP4*, *GK*, *GST*, *PPARA*, and *PPARG* may be associated with increased CVD risk in people with T2DM, but the evidence is inconclusive.[407]

Family history of premature CVD is an established and independent risk factor for the development of CVD.[408,409] For example, the AHA scientific statement on cardiovascular risk reduction in high-risk pediatric populations[4] identifies a family history of premature coronary artery disease in expanded first-degree pedigrees (corresponding to male family members <55 years of age and female family members <65 years of age) as a risk factor for CVD in patients with T1DM and T2DM. The ADA[3] and American Academy of Pediatrics[57] recommendations are similar. Collectively, the major professional organizations agree that family history of early CVD is a major risk factor for the development of early CVD in patients with both T1DM and T2DM. In patients with T1DM, family history of T2DM increased CVD[410] and in the DCCT/EDIC was associated with increased weight gain and a more atherogenic CVD profile among those in the intensive intervention arm in the highest quartile of weight gain.[411]

Gaps in Knowledge

Data from the observational studies add to our understanding of the pathophysiology and current clinical practices and highlight needs for improved care. Better methods of glucose control and management of other CVD risk factors are required for both T1DM and T2DM. The data from randomized, clinical trials such as the TODAY study in youth with T2D[60] and those anticipated from the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) study in youth with T1DM will begin to provide much-needed data on the management of CVD

risk factors in diabetes mellitus.[412] Participants in TODAY were treated for hypertension and dyslipidemia per study protocols, and although these were not the primary study aims, these longitudinal data will inform the management of these CVD risk factors in youth with T2DM. Similarly, the AdDIT study should soon provide data on the use of statins and angiotensin-converting enzyme inhibitors in adolescents with T1DM. Uncertainty remains for both the safety and efficacy of cardiovascular risk factor treatment in youth with diabetes mellitus (Table 3).

Given the current funding environment, it is unlikely that many of these research questions will be addressed in long-term, randomized, clinical trials. Pediatric providers will continue to need to combine various sources of evidence and to generate inferences from data in adults to determine the best possible treatment decisions for youth with diabetes mellitus and their families.

Summary/Priorities to Improve Cardiovascular Health

The most recent AHA/ADA position statement on the primary prevention of CVD in diabetes mellitus found that the current state of knowledge[413] did not allow the differentiation of guidelines for T1DM and T2DM. Moreover, the differentiation of T1DM and T2DM in youth can be challenging and is beyond the scope of this article.[414] However, >80% to 90% of youth diagnosed with T1DM will have evidence of autoimmunity, and T2DM is exceedingly rare in prepubescent children or in children with BMI <85th percentile for age and sex.[415] It remains an unanswered question as to whether pathophysiological differences exist in CVD risk in youth with T1DM and T2DM and, if so, whether preventive measures and therapeutics could be targeted more effectively. For example, pathophysiological differences could be presumed between two 15-year-olds, one with a recent diagnosis of autoimmune T1DM who is lean and the other with a BMI >99th percentile and T2DM. In contrast, IR is a well-established component of both T2DM and T1DM,[84,250]

Table 3. Gaps in Knowledge: Research Questions

What is the role for clinical trials of lifestyle interventions such as dietary and exercise modifications to improve CVD health?

What is the appropriate age to begin CVD risk factor screening?

What goals should be used for CVD risk factors?

At what age should pharmacological therapy be considered?

Should treatment goals for CVD risk factors be the same as those for adults or less or more stringent?

What are the risks of potential lifetime pharmacological treatment for CVD risk factors (or conversely of delaying such treatment until adulthood)?

What is the magnitude of teratogenic risk from pharmacological treatment of CVD risk factors in adolescent female patients?

What is the cost-benefit ratio of pharmacological treatment for CVD risk factors?

How will advances in glucose management such as the artificial pancreas affect CVD risk in T1DM?

How will population changes in obesity affect CVD risk in both T1DM and T2DM?

Do pathophysiological differences exist in CVD for T1DM vs T2DM?

CVD indicates cardiovascular disease; T1DM, type 1 diabetes mellitus; and T2DM, type 2 diabetes mellitus.

and youth with T1DM are increasingly obese instead of historically being thin as a result of poor glucose control.[221] Moreover, the DCCT/EDIC study suggests that intensive management of T1DM may result in increased BMI and associated CVD risk factors, especially in people with T1DM who have a family history of T2DM.[224,411,416] One might speculate that advances such as the artificial pancreas will improve glucose control but may also result in increases in obesity and possibly IR, with the cardiovascular risk factor profile in T1DM becoming more similar to those with T2DM. Therefore, although alternative strategies to reducing CVD risk in youth with diabetes mellitus are required, intensive glucose control remains the foundation of diabetes mellitus management. Priorities to improve cardiovascular health in youth with diabetes mellitus are listed in Table 4.

Conclusions

In this statement, we have reviewed recent guidelines[2–7] on CVD in youth with diabetes mellitus with an emphasis on new data that have emerged since their publication. Both T1DM and T2DM are increasing in youth, and current data indicate that elevated CVD risk factors are common but rarely treated pharmacologically.

Table 4. Priorities to Improve Cardiovascular Health in Youth With Diabetes Mellitus

Determination of appropriate screening guidelines for CVD risk factors
Recognition of cut points for initiation of treatment of CVD risk factors
Increasing rates of treatment of CVD risk factors
More information on associations of CVD risk factors with target organ damage (and the appropriate use of surrogate markers)
Better understanding of optimal treatment, including well-defined goals, and optimal levels for CVD risk factors
Improved methods to prevent development of early atherosclerosis
Safety and efficacy evaluations of pharmacological treatments targeting glucose control that offer additional pleiotropic CVD benefits

CVD indicates cardiovascular disease.

Clinical trial data are needed to inform the question of the appropriateness of pharmacological treatment of CVD risk factors. Prevention of future CVD in youth with diabetes mellitus will require advances in research and their translation to clinical care to prevent the development of CVD risk factors and to determine their optimal treatment when they do exist.

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/ Advisory Board	Other
Elaine Urbina	Cincinnati Children's Hospital	NIH/NHLBI†	None	None	None	None	None	None
David M. Maahs	University of Colorado Denver	Abbott Diabetes Care†; Eli Lilly†	None	None	None	None	None	None
Stephen R. Daniels	University of Colorado School of Medicine	None	None	None	None	None	DSMB for Merck*	None
Sarah D. de Ferranti	Boston Children's Heart Foundation	None	None	None	None	None	None	None
Helén L. Dichek	University of Washington	Takeda Pharmaceuticals (ended March 24, 2013)†	None	None	None	None	None	None
Joseph Flynn	Seattle Children's Hospital	NIH†	None	None	None	None	Pfizer DSMB member*	None
Benjamin I. Goldstein	Sunnybrook Health Sciences Centre	Pfizer*	None	Purdue Pharma*	None	None	Bristol-Myers Squibb*	None
Aaron S. Kelly	University of Minnesota	Amylin Pharmaceuticals†; NIH/NHLBI†; NIH Clinical and Translational Science Award†	None	None	None	None	Novo Nordisk*	None
Pamela Martyn-Nemeth	University of Illinois at Chicago	None	None	None	None	None	None	None
Kristen J. Nadeau	University of Colorado Denver	None	None	None	None	None	None	None
Stavroula K. Osganian	Boston Children's Hospital	GlaxoSmithKline†	None	None	None	None	None	None
Laurie Quinn	University of Illinois at Chicago	None	None	None	None	None	None	None
Amy S. Shah	Cincinnati Children's Hospital Medical Center	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/ Advisory Board	Other
Robert Eckel	University of Colorado	None	None	None	None	None	None	None
Samuel Gidding	Alfred I. duPont Hospital for Children	None	None	None	None	None	None	None
Rae-Ellen Kavey	University of Rochester	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

References

1. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, Lawrence JM, Liese AD, Liu LL, Mayer-Davis EJ, Rodriguez BL, Standiford D; SEARCH for Diabetes in Youth Study Group. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. *Diabetes Care*. 2012;35:2515–2520.
2. American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. *Diabetes Care*. 2003;26:2194–2197.
3. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N; American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. *Diabetes Care*. 2005;28:186–212.
4. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. *Circulation*. 2006;114:2710–2738.
5. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. *Circulation*. 2007;115:1948–1967.
6. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. *Pediatrics*. 2008;122:198–208.
7. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K; International Society for Pediatric and Adolescent Diabetes. ISPAD clinical practice consensus guidelines 2006–2007: microvascular and macrovascular complications. *Pediatr Diabetes*. 2007;8:163–170.
8. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213–S256.
9. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. *Endocrinol Metab Clin North Am*. 2010;39:481–497.
10. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. *Diabetes Care*. 2009;32:1769–1782.
11. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature*. 2010;464:1293–1300.
12. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one, I: survival, causes of death, and complications. *Diabetologia*. 1978;14:363–370.
13. Christlieb AR, Warram JH, Krolewski AS, Busick EJ, Ganda OP, Asmal AC, Soeldner JS, Bradley RF. Hypertension: the major risk factor in juvenile-onset insulin-dependent diabetics. *Diabetes*. 1981;30:90–96.
14. Dorman JS, LaPorte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes*. 1984;33:271–276.
15. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. *Am J Cardiol*. 1987;59:750–755.
16. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. *Am J Public Health*. 1991;81:1158–1162.
17. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia*. 2003;46:760–765.
18. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. *Diabetes*. 2006;55:1463–1469.
19. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, Cleland S, Leese GP, McKnight J, Morris AD, Pearson DW, Peden NR, Petrie JR, Philip S, Sattar N, Sullivan F, Colhoun HM. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish Registry Linkage Study. *PLoS Med*. 2012;9:e1001321.
20. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. *Diabetes Care*. 2006;29:2528–2538.
21. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005;353:2643–2653.
22. Colhoun HM, Rubens MB, Underwood SR, Fuller JH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. *J Am Coll Cardiol*. 2000;36:2160–2167.
23. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM: gender differences in risk factors but not risk. *Arterioscler Thromb Vasc Biol*. 1996;16:720–726.
24. Maahs DM, Hokanson JE, Wang H, Kinney GL, Snell-Bergeon JK, East A, Bergman BC, Schauer IE, Rewers M, Eckel RH. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. *Diabetes*. 2010;59:1771–1779.
25. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. *J Pediatr*. 1996;128(pt 1):608–615.
26. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. *J Pediatr*. 2005;146:693–700.
27. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. *JAMA*. 2006;296:421–426.
28. Sellers EA, Yung G, Dean HJ. Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation pediatric population with type 2 diabetes mellitus. *Pediatr Diabetes*. 2007;8:384–390.
29. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. *Circulation*. 2009;119:1728–1735.
30. Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J. Long-term complications and mortality in

young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. *Diabetes Care*. 2013;36:3863–3869.

31. Cefalu WT. "TODAY" reflects on the changing "faces" of type 2 diabetes. *Diabetes Care*. 2013;36:1732–1734.

32. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. *J Clin Endocrinol Metab*. 2012;97:4383–4389.

33. Lipton R, Good G, Mikhailov T, Freels S, Donoghue E. Ethnic differences in mortality from insulin-dependent diabetes mellitus among people less than 25 years of age. *Pediatrics*. 1999;103(pt 1):952–956.

34. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. *N Engl J Med*. 1993;329:977–986.

35. Wood JR, Miller KM, Maahs DM, Beck RW, Dimeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. *Diabetes Care*. 2013;36:2035–2037.

36. Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, Rodriguez H, Simmons JH, Hirsch IB. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A$_{1C}$ levels in T1D Exchange Clinic Registry participants. *Diabetes Care*. 2013;35:2009–2014.

37. Deleted in proof.

38. Pump use is higher in whites than minorities [abstract]. *Diabetes*. 2013;61(suppl) A345–A403.

39. Danielson KK, Drum ML, Estrada CL, Lipton RB. Racial and ethnic differences in an estimated measure of insulin resistance among individuals with type 1 diabetes. *Diabetes Care*. 2010;33:614–619.

40. SEARCH for Diabetes in Youth Study Group; Liese AD, D'Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu L, Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. *Pediatrics*. 2006;118:1510–1518.

41. Holland AT, Zhao B, Wong EC, Choi SE, Wong ND, Palaniappan LP. Racial/ethnic differences in control of cardiovascular risk factors among type 2 diabetes patients in an insured, ambulatory care population. *J Diabetes Complications*. 2013;27:34–40.

42. Shah AS, Dolan LM, Gao Z, Kimball TR, Urbina EM. Racial differences in arterial stiffness among adolescents and young adults with type 2 diabetes. *Pediatr Diabetes*. 2012;13:170–175.

43. DeBoer MD, Gurka MJ, Sumner AE. Diagnosis of the metabolic syndrome is associated with disproportionately high levels of high-sensitivity C-reactive protein in non-Hispanic black adolescents: an analysis of NHANES 1999–2008. *Diabetes Care*. 2011;34:734–740.

44. Mensah GA, Mokdad, AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. *Circulation*. 2005;111:1233–1241.

45. Maligie M, Crume T, Scherzinger A, Stamm E, Dabelea D. Adiposity, fat patterning, and the metabolic syndrome among diverse youth: the EPOCH study. *J Pediatr*. 2012;161:875–880.

46. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. *Arch Intern Med*. 2003;163:427–436.

47. Walker SE, Gurka MJ, Oliver MN, Johns DW, DeBoer MD. Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factors. *Nutr Metab Cardiovasc Dis*. 2012;22:141–148.

48. Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. *Atherosclerosis*. 2008;196:696–703.

49. Bacha F, Gungor N, Lee S, Arslanian SA. Type 2 diabetes in youth: are there racial differences in β-cell responsiveness relative to insulin sensitivity? *Pediatr Diabetes*. 2012;13:259–265.

50. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. *J Clin Endocrinol Metab*. 2003;88:2534–2540.

51. Cardel M, Higgins PB, Willig AL, Keita AD, Casazza K, Gower BA, Fernandez JR. African genetic admixture is associated with body composition and fat distribution in a cross-sectional study of children. *Int J Obes (Lond)*. 2011;35:60–65.

52. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. *Pediatr Diabetes*. 2009;10:5–13.

53. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. *Pediatrics*. 2005;115:e561–e565.

54. Bhalla V, Zhao B, Azar KM, Wang EJ, Choi S, Wong EC, Fortmann SP, Palaniappan LP. Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. *Diabetes Care* 2013;36:1215–1221.

55. American Diabetes Association. Standards of medical care in diabetes: 2014. *Diabetes Care*. 2014;37(suppl 1):S14–S80.

56. American Diabetes Association. Standards of medical care in diabetes: 2013. *Diabetes Care*. 2013;36(suppl 1):S11–S66.

57. Springer SC, Silverstein J, Copeland K, Moore KR, Prazar GE, Raymer T, Shiffman RN, Thaker VV, Anderson M, Spann SJ, Flinn SK. Management of type 2 diabetes mellitus in children and adolescents. *Pediatrics*. 2013;131:e648–e664.

58. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National High Blood Pressure Education Program Coordinating Committee. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213–S256.

59. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114(suppl 4th report):555–576.

60. TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*. 2012;366:2247–2256.

61. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ. Assessment and monitoring of glycemic control in children and adolescents with diabetes. *Pediatr Diabetes*. 2009;10(suppl 12):71–81.

62. Hatherly K, Smith L, Overland J, Johnston C, Brown-Singh L. Application of Australian clinical management guidelines: the current state of play in a sample of young people living with type 1 diabetes in the state of New South Wales and the Australian Capital Territory. *Diabetes Res Clin Pract*. 2011;93:379–384.

63. Hussain T, Bagnall A, Agwu JC. NICE guidelines for hyperlipidaemia in children and young people with type I diabetes: time for a rethink? *Arch Dis Child*. 2006;91:545.

64. Valent D, Pestak K, Otis M, Shubrook J. Type 2 diabetes in the pediatric population: are we meeting ADA clinical guidelines in Ohio? *Clin Pediatr (Phila)*. 2010;49:316–322.

65. Gosden C, Edge JA, Holt RI, James J, Turner B, Winocour P, Walton C, Nagi D, Williams R, Matyka K. The fifth UK paediatric diabetes services survey: meeting guidelines and recommendations? *Arch Dis Child*. 2010;95:837–840.

66. Waitzfelder B, Pihoker C, Klingensmith G, Case D, Anderson A, Bell RA, Lawrence JM, Mayer-Davis EJ, Imperatore G, Standiford D, Rodriguez BL, Dabelea D, Seid M; SEARCH for Diabetes in Youth Study Group. Adherence to guidelines for youths with diabetes mellitus. *Pediatrics*. 2011;128:531–538.

67. Peters A, Laffel L; American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). *Diabetes Care*. 2011;34:2477–2485.

68. Rodriguez BL, Dabelea D, Liese AD, Fujimoto W, Waitzfelder B, Liu L, Bell R, Talton J, Snively BM, Kershnar A, Urbina E, Daniels S, Imperatore G; SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. *J Pediatr*. 2010;157:245–251.e1.

69. Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Pettitt DJ, Marcovina S, Dolan LM, Hamman RF, Liese AD, Pihoker C, Rodriguez BL. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. *J Pediatr*. 2006;149:314–319.

70. Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, Kordonouri O, Beyer P, Holl RW; DPV Initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). *Diabetes Care*. 2006;29:218–225.

71. Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, Laffel LM, Miller KM, Speer H, Tamborlane WV, Tansey MJ; T1D Exchange Clinic Network. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. *Diabetes Care*. 2013;36:2639–2645.

72. Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. *Trends Cardiovasc Med*. 2010;20:90–95.

73. Freedman DS, Khan LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS. Racial differences in the tracking of childhood BMI to adulthood. *Obes Res*. 2005;13:928–935.

74. Burns TL, Letuchy EM, Paulos R, Witt J. Childhood predictors of the metabolic syndrome in middle-aged adults: the Muscatine study. *J Pediatr*. 2009;155:S5.17–S5.e26.

75. Juhola J, Magnussen CG, Viikari JS, Kahonen M, Hutri-Kahonen N, Jula A, Lehtimaki T, Akerblom HK, Pietikainen M, Laitinen T, Jokinen E, Taittonen L, Raitakari OT, Juonala M. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. *J Pediatr*. 2011;159:584–590.

76. Juonala M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kahonen M, Laitinen T, Taittonen L, Berenson GS, Viikari JS, Raitakari OT. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. *Circulation*. 2010;122:2514–2520.

77. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206–1252.

78. Cioffi G, Faggiano P, Lucci D, Di Lenarda A, Mureddu GF, Tarantini L, Verdecchia P, Comaschi M, Giorda CB, Velussi M, Chinali M, Latini R, Masson S, De Simone G; DYDA Investigators. Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease: the DYDA study. *J Hypertens*. 2011;29:1994–2003.

79. Moon SJ, Bae KS, Park HC, Kim JK, Park JT, Lee JE, Rim SJ, Ha SK. The effect of anemia and left ventricular geometric patterns on renal disease progression in type 2 diabetic nephropathy. *J Nephrol*. 2011;24:50–59.

80. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, Liu CY, Lima JA, Bluemke DA; DCCT/EDIC Research Group. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. *Circulation*. 2011;124:1737–1746.

81. van den Hurk K, Alssema M, Kamp O, Henry RM, Stehouwer CD, Smulders YM, Nijpels G, Paulus WJ, Dekker JM. Independent associations of glucose status and arterial stiffness with left ventricular diastolic dysfunction: an 8-year follow-up of the Hoorn Study. *Diabetes Care*. 2012;35:1258–1264.

82. Gul K, Celebi AS, Kacmaz F, Ozcan OC, Ustun I, Berker D, Aydin Y, Delibasi T, Guler S, Barazi AO. Tissue Doppler imaging must be performed to detect early left ventricular dysfunction in patients with type 1 diabetes mellitus. *Eur J Echocardiogr*. 2009;10:841–846.

83. Kim SA, Shim CY, Kim JM, Lee HJ, Choi DH, Choi EY, Jang Y, Chung N, Ha JW: Impact of left ventricular longitudinal diastolic functional reserve on clinical outcome in patients with type 2 diabetes mellitus. *Heart*. 2011;97:1233–1238.

84. Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. *J Clin Endocrinol Metab*. 2010;95:513–521.

85. Karavanaki K, Kazianis G, Konstantopoulos I, Tsouvalas E, Karayianni C. Early signs of left ventricular dysfunction in adolescents with type 1 diabetes mellitus: the importance of impaired circadian modulation of blood pressure and heart rate. *J Endocrinol Invest*. 2008;31:289–296.

86. Koken R, Demir T, Sen TA, Kundak AA, Oztekin O, Alpay F. The relationship between P-wave dispersion and diastolic functions in diabetic children. *Cardiol Young*. 2010;20:133–137.

87. Vazeou A, Papadopoulou A, Miha M, Drakatos A, Georgacopoulos D. Cardiovascular impairment in children, adolescents, and young adults with type 1 diabetes mellitus (T1DM). *Eur J Pediatr*. 2008;167:877–884.

88. Salem M, El Behery S, Adly A, Khalil D, El Hadidi E. Early predictors of myocardial disease in children and adolescents with type 1 diabetes mellitus. *Pediatr Diabetes*. 2009;10:513–521.

89. Wojcik M, Rudzinski A, Starzyk J. Left ventricular diastolic dysfunction in adolescents with type 1 diabetes reflects the long- but not short-term metabolic control. *J Pediatr Endocrinol Metab*. 2010;23:1055–1064.

90. Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. *J Clin Endocrinol Metab*. 2009;94:3687–3695.

91. Shah AS, Khoury PR, Dolan LM, Ippisch HM, Urbina EM, Daniels SR, Kimball TR. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. *Diabetologia*. 2011;54:722–730.

92. Harrington J, Pena AS, Gent R, Hirte C, Couper J. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. *J Pediatr*. 2010;156:237–241.

93. Heilman K, Zilmer M, Zilmer K, Lintrop M, Kampus P, Kals J, Tillmann V. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. *Diabetes Res Clin Pract*. 2009;84:168–173.

94. Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti MC, Spontoni P, Massart F, Salvi P, Balbarini A, Saggese G, Di Stefano R, Federico G. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. *Cardiovasc Diabetol*. 2011;10:88.

95. Rabago Rodriguez R, Gomez-Diaz RA, Tanus Hanj J, Avelar Garnica FJ, Ramirez Soriano E, Nishimura Meguro E, Aguilar-Salinas CA, Wacher NH. Carotid intima-media thickness in pediatric type 1 diabetic patients. *Diabetes Care*. 2007;30:2599–2602.

96. Trigona B, Aggoun Y, Maggio A, Martin XE, Marchand LM, Beghetti M, Farpour-Lambert NJ. Preclinical noninvasive markers of atherosclerosis in children and adolescents with type 1 diabetes are influenced by physical activity. *J Pediatr*. 2010;157:533–539.

97. Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. *Diabetes Care*. 2010;33:2043–2048.

98. Odermarsky M, Lykkesfeldt J, Liuba P. Poor vitamin C status is associated with increased carotid intima-media thickness, decreased microvascular function, and delayed myocardial repolarization in young patients with type 1 diabetes. *Am J Clin Nutr*. 2009;90:447–452.

99. Dalla Pozza R, Bechtold S, Bonfig W, Putzker S, Kozlik-Feldmann R, Netz H, Schwarz HP. Age of onset of type 1 diabetes in children and carotid intima medial thickness. *J Clin Endocrinol Metab*. 2007;92:2053–2057.

100. Krebs A, Schmidt-Trucksass A, Doerfer J, Grulich-Henn J, Holder M, Hecker W, Krebs K, Barth M, Schwab KO. Cardiovascular risk in pediatric type 1 diabetes: sex-specific intima-media thickening verified by automatic contour identification and analyzing systems. *Pediatr Diabetes*. 2012;13:251–258.

101. Naylor LH, Green DJ, Jones TW, Kalic RJ, Suriano KL, Shah M, Hopkins N, Davis EA. Endothelial function and carotid intima-medial thickness in adolescents with type 2 diabetes mellitus. *J Pediatr*. 2011;159:971–974.

102. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM. Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. *Circulation*. 2009;119:2913–2919.

103. Kotb NA, Gaber R, Salama M, Nagy HM, Elhendy A. Clinical and biochemical predictors of increased carotid intima-media thickness in overweight and obese adolescents with type 2 diabetes. *Diab Vasc Dis Res*. 2012;9:35–41.

104. Shah AS, Dolan LM, Kimball TR, Gao Z, Khoury PR, Daniels SR, Urbina EM. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2009;94:3740–3745.

105. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. *Atherosclerosis*. 2009;204:288–292.

106. Dalla Pozza R, Netz H, Schwarz HP, Bechtold S. Subclinical atherosclerosis in diabetic children: results of a longitudinal study. *Pediatr Diabetes*. 2010;11:129–133.

107. Dalla Pozza R, Beyerlein A, Thilmany C, Weissenbacher C, Netz H, Schmidt H, Bechtold S. The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus. *Cardiovasc Diabetol*. 2011;10:53.

108. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, Nathan DM; DCCT/EDIC Research Group. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes*. 2011;60:607–613.

109. Atabek ME, Kurtoglu S, Selver B, Baykara M. Effectiveness of pentoxifylline on the cross-sectional area of intima media thickness and functions of the common carotid artery in adolescents with type 1 diabetes. *J Pediatr Endocrinol Metab*. 2011;24:945–951.

110. Galler A, Heitmann A, Siekmeyer W, Gelbrich G, Kapellen T, Kratzsch J, Kiess W. Increased arterial stiffness in children and adolescents with type 1 diabetes: no association between arterial stiffness and serum levels of adiponectin. *Pediatr Diabetes*. 2010;11:38–46.

111. Urbina EM, Wadwa RP, Davis C, Snively BM, Dolan LM, Daniels SR, Hamman RF, Dabelea D. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. *J Pediatr*. 2010;156:731–737, 737.e1.

112. Krishnan S, Copeland KC, Bright BC, Gardner AW, Blackett PR, Fields DA. Impact of type 1 diabetes and body weight status on cardiovascular risk factors in adolescent children. *J Clin Hypertens (Greenwich)*. 2011;13:351–356.

113. Yu MC, Lo FS, Yu MK, Huang WH, Lee F. Arterial stiffness is not increased in teens with early uncomplicated type 1 diabetes mellitus. *Eur J Pediatr*. 2012;171:855–858.

114. Urbina EM, Kimball TR, Khoury PR, Daniels SR, Dolan LM. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. *J Hypertens*. 2010;28:1692–1698.

115. Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, Pepine C, Silverstein JH. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2009;22:65–68.

116. Babar GS, Zidan H, Widlansky ME, Das E, Hoffmann RG, Daoud M, Alemzadeh R. Impaired endothelial function in preadolescent children with type 1 diabetes. *Diabetes Care*. 2011;34:681–685.

117. Pena AS, Couper JJ, Harrington J, Gent R, Fairchild J, Tham E, Baghurst P. Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. *Diabetes Technol Ther*. 2012;14:457–462.

118. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. *Pediatr Diabetes*. 2007;8:193–198.

119. Mahmud, FH, Van Uum S, Kanji N, Thiessen-Philbrook H, Clarson CL. Impaired endothelial function in adolescents with type 1 diabetes mellitus. *J Pediatr*. 2008;152:557–562.

120. DiMeglio LA, Tosh A, Saha C, Estes M, Mund J, Mead LE, Lien I, Ingram DA, Haneline LS. Endothelial abnormalities in adolescents with type 1 diabetes: a biomarker for vascular sequelae? *J Pediatr*. 2010;157:540–546.

121. Ce GV, Rohde LE, da Silva AM, Punales MK, de Castro AC, Bertoluci MC. Endothelial dysfunction is related to poor glycemic control in adolescents with type 1 diabetes under 5 years of disease: evidence of metabolic memory. *J Clin Endocrinol Metab*. 2011;96:1493–1499.

122. Roche DM, Edmunds S, Cable T, Didi M, Stratton G. Skin microvascular reactivity in children and adolescents with type 1 diabetes in relation to levels of physical activity and aerobic fitness. *Pediatr Exerc Sci*. 2008;20:426–438.

123. MacKenzie KE, Wiltshire EJ, Pena AS, Gent R, Hirte C, Piotto L, Couper JJ. Hs-CRP is associated with weight, BMI, and female sex but not with endothelial function in children with type 1 diabetes. *Pediatr Diabetes*. 2009;10:44–51.

124. Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. *J Clin Endocrinol Metab*. 2010;95:513–521.

125. Seeger JP, Thijssen DH, Noordam K, Cranen ME, Hopman MT, Nijhuis-van der Sanden MW. Exercise training improves physical fitness and vascular function in children with type 1 diabetes. *Diabetes Obes Metab*. 2011;13:382–384.

126. Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. *Diabetologia*. 2008;51:353–360.

127. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. *J Diabetes Complications*. 2007;21:13–19.

128. Lee SS, Han HS, Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. *Pediatr Diabetes*. 2010;11:521–528.

129. Boysen A, Lewin MA, Hecker W, Leichter HE, Uhlemann F. Autonomic function testing in children and adolescents with diabetes mellitus. *Pediatr Diabetes*. 2007;8:261–264.

130. Dalla Pozza R, Bechtold S, Bonfig W, Putzker S, Kozlik-Feldmann R, Schwarz HP, Netz H. Impaired short-term blood pressure regulation and autonomic dysbalance in children with type 1 diabetes mellitus. *Diabetologia*. 2007;50:2417–2423.

131. Lucini D, Zuccotti G, Malacarne M, Scaramuzza A, Riboni S, Palombo C, Pagani M. Early progression of the autonomic dysfunction observed in pediatric type 1 diabetes mellitus. *Hypertension*. 2009;54:987–994.

132. Jaiswal M, Urbina EM, Wadwa RP, Talton JW, D'Agostino RB Jr, Hamman RF, Fingerlin TE, Daniels S, Marcovina SM, Dolan LM, Dabelea D. Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. *Diabetes Care*. 2013;36:157–162.

133. Chen SR, Lee YJ, Chiu HW, Jeng C. Impact of physical activity on heart rate variability in children with type 1 diabetes. *Childs Nerv Syst*. 2008;24:741–747.

134. Yau PL, Javier DC, Ryan CM, Tsui WH, Ardekani BA, Ten S, Convit A. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. *Diabetologia*. 2010;53:2298–2306.

135. Karabouta Z, Barnett S, Shield JP, Ryan FJ, Crowne EC. Peripheral neuropathy is an early complication of type 2 diabetes in adolescence. *Pediatr Diabetes*. 2008;9:110–114.

136. Faulkner MS, Quinn L, Fritschi C. Microalbuminuria and heart rate variability in adolescents with diabetes. *J Pediatr Health Care*. 2010;24:34–41.

137. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. *Diabetes Care*. 2010;33:652–657.

138. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol*. 2008;126:1707–1715.

139. Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, Musen G, Dahms W; Diabetes Control and Complications Trial/EDIC Research Group. Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. *Diabetologia*. 2011;54:245–255.

140. Benitez-Aguirre P, Craig ME, Sasongko MB, Jenkins AJ, Wong TY, Wang JJ, Cheung N, Donaghue KC. Retinal vascular geometry predicts incident retinopathy in young people with type 1 diabetes: a prospective cohort study from adolescence. *Diabetes Care* . 2011;34:1622–1627.

141. Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. *Diabetes Care*. 2008;31:1842–1846.

142. Lim SW, Cheung N, Wang JJ, Donaghue KC, Liew G, Islam FM, Jenkins AJ, Wong TY. Retinal vascular fractal dimension and risk of early diabetic retinopathy: a prospective study of children and adolescents with type 1 diabetes. *Diabetes Care*. 2009;32:2081–2083.

143. Bronson-Castain KW, Bearse MA Jr, Neuville J, Jonasdottir S, King-Hooper B, Barez S, Schneck ME, Adams AJ. Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. *Retina*. 2012;32:92–102.

144. TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. *Diabetes Care*. 2013;36:1772–1774.

145. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, Cusumano J, Pryke A, Craig ME. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. *Diabetes Care*. 2011;34:1400–1402.

146. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. *BMJ*. 2008;337:a918.

147. Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. *Diabetes Care*. 2011;34:2368–2373.

148. Craig ME, Duffin AC, Gallego PH, Lam A, Cusumano J, Hing S, Donaghue KC. Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. *Diabetes Care*. 2008;31:1201–1206.

149. Kubin M, Tossavainen P, Hannula V, Lahti S, Hautala N, Falck A. Prevalence of retinopathy in Finnish children and adolescents with type 1 diabetes: a cross-sectional population-based retrospective study. *Arch Dis Child*. 2011;96:963–968.

150. Cho YH, Couper JJ, Donaghue KC. Complications of childhood diabetes and the role of technology. *Pediatr Endocrinol Rev*. 2010;7(suppl 3):422–431.

151. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD; DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. *Diabetes*. 2010;59:1244–1253.

151a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352:854–865.

152. Deleted in proof.

153. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA*. 2003;290:2159–2167.

154. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes Care*. 2003;26:1374–1379.

155. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. *Diabetes Care*. 2004;27:530–537.

156. Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, Moss SE, Reinke JO. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Arch Intern Med*. 2004;164:1917–1924.

157. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, Jacobson M, Mahoney L, Mietus-Snyder M, Rocchini A, Steinberger J, McCrindle B; on behalf of the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. *Hypertension*. 2009;54:919–950.

158. Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. *J Pediatr*. 2004;145:452–457.

159. Haller MJ, Samyn M, Nichols WW, Brusko T, Wasserfal, C, Schwartz RF, Atkinson M, Shuster JJ, Pierce GL, Silverstein JH. Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes. *Diabetes Care*. 2004;27:2911–2917.

160. Wadwa RP, Urbina EM, Anderson AM, Hamman RF, Dolan LM, Rodriguez BL, Daniels SR, Dabelea D; SEARCH Study Group. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. *Diabetes Care*. 2010;33:881–886.

161. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352:837–853.

162. Deleted in proof.

163. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359:1577–1589.

164. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405–412.

165. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–2572.

166. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360:129–139.

167. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. *Diabetes Care*. 2010;33:983–990.

168. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358:2545–2559.

169. Shah AS, Dolan LM, Kimball TR, Gao Z, Khoury PR, Daniels SR, Urbina EM. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2009;94:3740–3745.

170. Knerr I, Dost A, Lepler R, Raile K, Schober E, Rascher W, Holl RW; Diabetes Data Acquisition System for Prospective Surveillance (DPV) Scientific Initiative Germany and Austria. Tracking and prediction of arterial blood pressure from childhood to young adulthood in 868 patients with type 1 diabetes: a multicenter longitudinal survey in Germany and Austria. *Diabetes Care*. 2008;31:726–727.

171. Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jorgensen K; Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. *Diabetologia*. 2008;51:554–561.

172. Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab*. 2011;96:159–167.

173. Mayer-Davis EJ, Ma B, Lawson A, D'Agostino RB Jr, Liese AD, Bell RA, Dabelea D, Dolan L, Pettitt DJ, Rodriguez BL, Williams D; SEARCH for Diabetes in Youth Study Group. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. *Metab Syndr Relat Disord*. 2009;7:89–95.

174. Delaney A, Pellizzari M, Speiser PW, Frank GR. Pitfalls in the measurement of the nocturnal blood pressure dip in adolescents with type 1 diabetes. *Diabetes Care*. 2009;32:165–168.

175. Sulakova T, Janda J, Cerna J, Janstova V, Sulakova A, Slany J, Feber J. Arterial HTN in children with T1DM: frequent and not easy to diagnose. *Pediatr Diabetes*. 2009;10:441–448.

176. Basiratnia M, Abadi SF, Amirhakimi GH, Karamizadeh Z, Karamifar H. Ambulatory blood pressure monitoring in children and adolescents with type-1 diabetes mellitus and its relation to diabetic control and microalbuminuria. *Saudi J Kidney Dis Transpl*. 2012;23:311–315.

177. Stergiou GS, Alamara C, Drakatos A, Stefanidis CJ, Vazeou A. Prediction of albuminuria by different blood pressure measurement methods in type 1 diabetes: a pilot study. *Hypertens Res*. 2009;32:680–684.

178. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. *Diabetes Care*. 2007;30:2523–2528.

179. Lee SH, Kim JH, Kang MJ, Lee YA, Won YS, Shin CH. Implications of nocturnal hypertension in children and adolescents with type 1 diabetes. *Diabetes Care*. 2011;34:2180–2185.

180. Schwab KO, Doerfer J, Krebs A, Krebs K, Schorb E, Hallermann K, Superti-Furga A, Zieger B, Marz W, Schmidt-Trucksass A, Winkler K. Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia. *Eur J Pediatr*. 2007;166:541–548.

181. Gunther AL, Liese AD, Bell RA, Dabelea D, Lawrence JM, Rodriguez BL, Standiford DA, Mayer-Davis EJ. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. *Hypertension*. 2009;53:6–12.

182. Pietrzak I, Mianowska B, Gadzicka A, Mlynarski W, Szadkowska A. Blood pressure in children and adolescents with type 1 diabetes mellitus: the influence of body mass index and fat mass. *Pediatr Endocrinol Diabetes Metab*. 2009;15:240–245.

183. Valerio G, Iafusco D, Zucchini S, Maffeis C; Study-Group on Diabetes of Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. *Diabetes Res Clin Pract*. 2012;97:99–104.

184. Krause M, Rudiger H, Bald M, Nake A, Paditz E. Autonomic blood pressure control in children and adolescents with type 1 diabetes mellitus. *Pediatr Diabetes*. 2009;10:255–263.

185. Chatterjee M, Speiser PW, Pellizzarri M, Carey DE, Fort P, Kreitzer PM, Frank GR. Poor glycemic control is associated with abnormal changes in 24-hour ambulatory blood pressure in children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2009;22:1061–1067.

186. Dost A, Klinkert C, Kapellen T, Lemmer A, Naeke A, Grabert M, Kreuder J, Holl RW; DPV Science Initiative. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. *Diabetes Care*. 2008;31:720–725.

187. Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, Howard WJ, Russell M, Wilson C, Ratner R, Sorkin J, Umans JG, Fleg JL, Stylianou M, Lee E, Howard BV. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. *J Clin Hypertens (Greenwich)*. 2009;11:540–548.

188. Shankar A, Klein R, Klein BE, Nieto FJ, Moss SE. Relationship between low-normal blood pressure and kidney disease in type 1 diabetes. *Hypertension*. 2007;49:48–54.

189. Osher E, Stern N. Diastolic pressure in type 2 diabetes: can target systolic pressure be reached without "diastolic hypotension"? *Diabetes Care*. 2008;31(suppl 2):S249–S254.

190. Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. *J Clin Hypertens (Greenwich)*. 2011;13:332–342.

191. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. *N Engl J Med*. 1998;338:1650–1656.

192. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. *JAMA*. 1999;281:727–735.

193. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143–3421.

194. Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein: a deep-etch and immunolocalization study of ultrarapidly frozen tissue. *Arterioscler Thromb*. 1991;11:1795–1805.

195. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*. 2006;354:1264–1272.

196. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, II: selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. *Arteriosclerosis*. 1989;9:908–918.

197. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation*. 2007;116:1832–1844.

198. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. *Pediatrics*. 2007;120:e189–e214.

199. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685–696.

200. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. *Lancet*. 2004;363:369–370.

201. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2002;40:2117–2121.

202. Edge JA, James T, Shine B. Longitudinal screening of serum lipids in children and adolescents with type 1 diabetes in a UK clinic population. *Diabet Med*. 2008;25:942–948.

203. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD, Edge J, Neil A, Shield J, Widmer B, Todd JA, Dunger DB. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. *Diabetes Care*. 2009;32:658–663.

204. Reh CM, Mittelman SD, Wee CP, Shah AC, Kaufman FR, Wood JR. A longitudinal assessment of lipids in youth with type 1 diabetes. *Pediatr Diabetes*. 2011;12(pt 2):365–371.

205. Maahs DM, Wadwa RP, McFann K, Nadeau K, Williams MR, Eckel RH, Klingensmith GJ. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. *J Pediatr*. 2007;150:146–150, 150.e1–150.e1.

206. Maahs DM, Dabelea D, D'Agostino RB Jr, Andrews JS, Shah AS, Crimmins N, Mayer-Davis EJ, Marcovina S, Imperatore G, Wadwa RP, Daniels SR, Reynolds K, Hamman RF, Dolan LM; SEARCH for Diabetes in Youth Study. Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes. *J Pediatr*. 2013;162:101–107.e1.

207. Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, D'Agostino R Jr, Marcovina S, Dabelea D. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. *Diabetes Care*. 2009;32:416–420.

208. Schwab KO, Doerfer J, Naeke A, Rohrer T, Wiemann D, Marg W, Hofer SE, Holl RW; German/Austrian Pediatric DPV Initiative. Influence of food intake, age, gender, HbA1c, and BMI levels on plasma cholesterol in 29,979 children and adolescents with type 1 diabetes: reference data from the German diabetes documentation and quality management system (DPV). *Pediatr Diabetes*. 2009;10:184–192.

209. Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK, Marcovina S, Pettitt DJ, Pihoker C; SEARCH for Diabetes in Youth Study. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. *Arch Pediatr Adolesc Med*. 2007;161:159–165.

210. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013;36:1758–1764.

211. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-$_{1c}$ mRNA in the livers of rats with streptozotocin-induced diabetes. *Proc Natl Acad Sci USA*. 1999;96:13656–13661.

212. Maahs DM, Wadwa RP, Bishop F, Daniels SR, Rewers M, Klingensmith GJ. Dyslipidemia in youth with diabetes: to treat or not to treat? *J Pediatr*. 2008;153:458–465.

213. Klopfleisch S, Merkler D, Schmitz M, Kloppner S, Schedensack M, Jeserich G, Althaus HH, Bruck W. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. *J Neurosci*. 2008;28:13609–13614.

214. Miron VE, Zehntner SP, Kuhlmann T, Ludwin SK, Owens T, Kennedy TE, Bedell BJ, Antel JP. Statin therapy inhibits remyelination in the central nervous system. *Am J Pathol*. 2009;174:1880–1890.

215. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. *J Am Coll Cardiol*. 2012;60:875–881.

216. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. *Mayo Clin Proc*. 2013;88:1213–1221.

217. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM. Statins and cognitive function: a systematic review. *Ann Intern Med*. 2013;159:688–697.

218. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. 1990;323:1289–1298.

219. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med*. 2011;365:2078–2087.

220. Glaser NS, Geller DH, Haqq A, Gitelman S, Malloy M; Lawson Wilkins Pediatric Endocrine Society Committee on Drugs and Therapeutics.

Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population? *Pediatr Diabetes*. 2011;12(pt 2):442–459.

221. Liu LL, Lawrence JM, Davis C, Liese AD, Pettitt DJ, Pihoker C, Dabelea D, Hamman R, Waitzfelder B, Kahn HS; SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. *Pediatr Diabetes*. 2010;11:4–11.

222. Nansel TR, Lipsky LM, Iannotti RJ. Cross-sectional and longitudinal relationships of body mass index with glycemic control in children and adolescents with type 1 diabetes mellitus. *Diabetes Res Clin Pract*. 2013;100:126–132.

223. Purnel JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. *JAMA*. 1998;280:140–146.

224. Purnell JQ, Zinman B, Brunzell JD; DCCT/EDIC Research Group. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. *Circulation*. 2013;127:180–187.

225. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, Springer SC, Thaker VV, Anderson M, Spann SJ, Flinn SK; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. *Pediatrics*. 2013;131:364–382.

226. Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH, Osganian SV, Feldman HA; Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. *Arch Pediatr Adolesc Med*. 2010;164:116–123.

227. Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, Kibirige M, Mathew V, Matyka K, McGovern A, Stirling H, Tetlow L, Wales J, Wright N, Clayton P, Hall C. Metformin in Obese Children and Adolescents: the MOCA Trial. *J Clin Endocrinol Metab*. 2013;98:322–329.

228. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. *Diabetes*. 2011;60:477–485.

229. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. *Diabetes*. 2013;62:2595–2604.

230. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering M, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. *Obesity (Silver Spring)*. 2012;20:364–370,

231. Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. *JAMA Pediatr*. 2013;167:355–360.

232. Alqahtani AR, Antonisamy B, Alamri H, Elahmedi M, Zimmerman VA. Laparoscopic sleeve gastrectomy in 108 obese children and adolescents aged 5 to 21 years. *Ann Surg*. 2012;256:266–273.

233. Inge TH, Jenkins TM, Zeller M, Dolan L, Daniels SR, Garcia VF, Brandt ML, Bean J, Gamm K, Xanthakos SA. Baseline BMI is a strong predictor of nadir BMI after adolescent gastric bypass. *J Pediatr*. 2010;156:103–108.

234. O'Brien PE, Sawyer SM, Laurie C, Brown WA, Skinner S, Veit F, Paul E, Burton PR, McGrice M, Anderson M, Dixon JB. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. *JAMA*. 2010;303:519–526.

235. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. *JAMA*. 2013;309:2240–2249.

236. Inge TH, Miyano G, Bean J, Helmrath M, Courcoulas A, Harmon CM, Chen MK, Wilson K, Daniels SR, Garcia VF, Brandt ML, Dolan LM. Reversal of type 2 diabetes mellitus and improvements in

cardiovascular risk factors after surgical weight loss in adolescents. *Pediatrics*. 2009;123:214–222.

237. Regensteiner JG, Bauer TA, Reusch JE, Quaife RA, Chen MY, Smith SC, Miller TM, Groves BM, Wolfel EE. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. *Med Sci Sports Exerc*. 2009;41:977–984.

238. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P; Insulin Resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. *Diabetes Care*. 2004;27:781–787.

239. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. *Diabetes Care*. 1999;22:562–568.

240. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? *Diabetes*. 2000;49:626–632.

241. Dabelea D, D'Agostino RB Jr, Mason CC, West N, Hamman RF, Mayer-Davis EJ, Maahs D, Klingensmith G, Knowler WC, Nadeau K. Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study. *Diabetologia*. 2011;54:78–86.

242. Luo GC, Liang Z, Hu QH, Yan DW, Lu LB, Gu WH, Chen ZL, Li HY, Liu MM. Evaluation of insulin resistance in type 1 diabetes with euglycemic-hyperinsulinemic clamp [in Chinese]. *Zhonghua Nei Ke Za Zhi*. 2009;48:10–12.

243. Maahs DM, Nadeau K, Snell-Bergeon JK, Schauer I, Bergman B, West NA, Rewers M, Daniels SR, Ogden LG, Hamman RF, Dabelea D. Association of insulin sensitivity to lipids across the lifespan in people with type 1 diabetes. *Diabet Med*. 2011;28:148–155.

244. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. *Pediatr Diabetes*. 2008;9:9–16.

245. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D'Agostino RB Jr, Hamman RF, Dabelea D. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. *J Clin Endocrinol Metab*. 2010;95:2868–2876.

246. Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, Bergman BC, Kinney GL, Rewers M. Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. *Diabet Med*. 2010;27:1436–1442.

247. Olson JC, Erbey JR, Williams KV, Becker DJ, Edmundowicz D, Kelsey SF, Tyrrell KS, Orchard TJ. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. *Ann Epidemiol*. 2002;12:331–337.

248. Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus. *J Clin Endocrinol Metab*. 2002;87:1036–1040.

249. Rodrigues TC, Veyna AM, Haarhues MD, Kinney GL, Rewers M, Snell-Bergeon JK. Obesity and coronary artery calcium in diabetes: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. *Diabetes Technol Ther*. 2011;13:991–996.

250. Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. *J Clin Endocrinol Metab*. 2009;94:3687–3695.

251. Urbina EM, Gao Z, Khoury PR, Martin LJ, Dolan LM. Insulin resistance and arterial stiffness in healthy adolescents and young adults. *Diabetologia*. 2012;55:625–631.

252. Cerutti F, Rabbia F, Rabbone I, Bobbio A, Ignaccolo MG, Greco G, Bertello MC, Mulatero P, Veglio F, Pacini G. Impairment of cardiovascular autonomic pattern in obese adolescents with type 2 diabetes mellitus. *J Endocrinol Invest*. 2010;33:539–543.

253. Perez-Mendez O, Torres-Tamayo M, Posadas-Romero C, Vidaure Garces V, Carreon-Torres E, Mendoza-Perez E, Medina Urrutia A, Huesca-Gomez C, Zamora-Gonzalez J, Aguilar-Herrera B. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. *Clin Chim Acta*. 2007;376:17–22.

254. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. *Diabetes*. 2011;60:477–485.

255. Yki-Jarvinen H. Thiazolidinediones. *N Engl J Med*. 2004;351:1106–1118.
256. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. *Diabetologia*. 2001;44:2210–2219.
257. Bell LM, Watts K, Siafarikas A, Thompson A, Ratnam N, Bulsara M, Finn J, O'Driscoll G, Green DJ, Jones TW, Davis EA. Exercise alone reduces insulin resistance in obese children independently of changes in body composition. *J Clin Endocrinol Metab*. 2007;92:4230–4235.
258. Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. *Diabetes*. 2012;61:2787–2795.
259. Vitola BE, Deivanayagam S, Stein RI, Mohammed BS, Magkos F, Kirk EP, Klein S. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. *Obesity (Silver Spring)*. 2009;17:1744–1748.
260. Savoye M, Nowicka P, Shaw M, Yu S, Dziura J, Chavent G, O'Malley G, Serrecchia JB, Tamborlane WV, Caprio S. Long-term results of an obesity program in an ethnically diverse pediatric population. *Pediatrics*. 2011;127:402–410.
261. de Moura EG, Orso IR, Martins BC, Lopes GS, de Oliveira SL, Galvao-Neto Mdos MP, Mancini MC, Santo MA, Sakai P, Ramos AC, Garrido-Junior AB, Halpern A, Cecconello I. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. *Obes Surg*. 2011;21:941–947.
262. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. *Diabetes Res Clin Pract*. 2007;76:12–17.
263. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M. Elevated C-reactive protein levels in the development of type 1 diabetes. *Diabetes*. 2004;53:2569–2573.
264. Karavanaki K, Kakleas K, Georga S, Bartzeliotou A, Mavropoulos G, Tsouvalas M, Vogiatzi A, Papassotiriou I, Karayianni C. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. *Clin Biochem*. 2012;45:1383–1388.
265. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D'Agostino RB Jr, Hamman RF, Dabelea D. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. *J Clin Endocrinol Metab*. 2010;95:2868–2876.
266. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. *Exp Clin Endocrinol Diabetes*. 2004;112:378–382.
267. Zineh I, Beitelshees AL, Silverstein JH, Haller MJ. Serum monocyte chemoattractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. *Diabetes Care*. 2009;32:465–467.
268. Verrijn Stuart AA, Schipper HS, Tasdelen I, Egan DA, Prakken BJ, Kalkhoven E, de Jager W. Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. *J Clin Endocrinol Metab*. 2012;97:463–472.
269. Deleted in proof.
270. Deleted in proof.
271. Stringer DM, Sellers EA, Burr LL, Taylor CG. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. *Pediatr Diabetes*. 2009;10:269–277.
272. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, Makdissi A, Dandona P. Exenatide exerts a potent antiinflammatory effect. *J Clin Endocrinol Metab*. 2012;97:198–207.
273. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation*. 2002;106:679–684.
274. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care*. 2010;33:177–183.
275. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. *Vasc Med*. 2007;12:311–318.
276. Kelly AS, Bank AJ. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. *J Diabetes Complications*. 2007;21:326–334.
277. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*. 2006;295:1681–1687.
278. Codoner-Franch P, Pons-Morales S, Boix-Garcia L, Valls-Belles V. Oxidant/antioxidant status in obese children compared to pediatric patients with type 1 diabetes mellitus. *Pediatr Diabetes*. 2010;11:251–257.
279. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. *Diabetes Care*. 1998;21:1736–1742.
280. Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJ. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. *Diabetes Metab Res Rev*. 1999;15:405–411.
281. Hata I, Kaji M, Hirano S, Shigematsu Y, Tsukahara H, Mayumi M. Urinary oxidative stress markers in young patients with type 1 diabetes. *Pediatr Int*. 2006;48:58–61.
282. Hsu WT, Tsai LY, Lin SK, Hsiao JK, Chen BH. Effects of diabetes duration and glycemic control on free radicals in children with type 1 diabetes mellitus. *Ann Clin Lab Sci*. 2006;36:174–178.
283. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Oxidative stress in childhood type 1 diabetes: results from a study covering the first 20 years of evolution. *Free Radic Res*. 2007;41:919–928.
284. Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF. Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. *Pediatr Diabetes*. 2006;7:51–59.
285. Kostolanska J, Jakus V, Barak L. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2009;22:433–442.
286. Gleisner A, Martinez L, Pino R, Rojas IG, Martinez A, Asenjo S, Rudolph MI. Oxidative stress markers in plasma and urine of prepubertal patients with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2006;19:995–1000.
287. Shamir R, Kassis H, Kaplan M, Naveh T, Shehadeh N. Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress. *Pediatr Diabetes*. 2008;9:104–109.
288. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. *Circulation*. 2003;107:3199–3203.
289. Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJ. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. *Diabetes Metab Res Rev*. 1999;15:405–411.
290. Deleted in proof.
291. Suys B, de Beeck LO, Rooman R, Kransfeld S, Heuten H, Goovaerts I, Vrints C, de Wolf D, Matthys D, Manuel-y-Keenoy B. Impact of oxidative stress on the endothelial dysfunction of children and adolescents with type 1 diabetes mellitus: protection by superoxide dismutase? *Pediatr Res*. 2007;62:456–461.
292. Gupta S, Sharma TK, Kaushik GG, Shekhawat VP. Vitamin E supplementation may ameliorate oxidative stress in type 1 diabetes mellitus patients. *Clin Lab*. 2011;57:379–386.
293. Maric C, Hall JE. Obesity, metabolic syndrome and diabetic nephropathy. *Contrib Nephrol*. 2011;170:28–35.
294. Amin R, Turner C, van Aken S, Bahu TK, Watts A, Lindsell DR, Dalton RN, Dunger DB. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: the Oxford Regional Prospective Study. *Kidney Int*. 2005;68:1740–1749.
295. Ficociello LH, Perkins BA, Roshan B, Weinberg JM, Aschengrau A, Warram JH, Krolewski AS. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. *Diabetes Care*. 2009;32:889–893.
296. Thomas MC, Moran JL, Harjutsalo V, Thorn L, Waden J, Saraheimo M, Tolonen N, Leiviska J, Jula A, Forsblom C, Groop PH; FinnDiane Study Group. Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy? *Diabetologia*. 2012;55:1505–1513.
297. Steinke JM, Mauer M; International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. *Pediatr Endocrinol Rev*. 2008;5(suppl 4):958–963.

298. Drummond K, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes, II: early renal structural changes in type 1 diabetes. *Diabetes*. 2002;51:1580–1587.

299. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes, III: predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. *Diabetes*. 2005;54:2164–2171.

300. Perrin NE, Torbjornsdotter T, Jaremko GA, Berg UB. Risk markers of future microalbuminuria and hypertension based on clinical and morphological parameters in young type 1 diabetes patients. *Pediatr Diabetes*. 2010;11:305–313.

301. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. *Diabetes Care*. 2006;29:1300–1306.

302. Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, Linder B, Marcovina SM, Mayer-Davis EJ, Pettitt DJ, Rodriguez BL, Dabelea D. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. *Diabetes Care*. 2007;30:2593–2598.

303. Kim NH, Pavkov ME, Knowler WC, Hanson RL, Weil EJ, Curtis JM, Bennett PH, Nelson RG. Predictive value of albuminuria in American Indian youth with or without type 2 diabetes. *Pediatrics*. 2010;125:e844–e851.

304. Sellers EA, Blydt-Hansen TD, Dean HJ, Gibson IW, Birk PE, Ogborn M. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. *Diabetes Care*. 2009;32:786–790.

305. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999–2008. *Pediatrics*. 2012;129:1035–1041.

306. Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. *Pediatr Res*. 2009;65:691–695.

307. Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. *J Pediatr*. 2005;147:67–73.

308. Salem M, Moneir I, Adly AM, Esmat K. Study of coronary artery calcification risk in Egyptian adolescents with type-1 diabetes. *Acta Diabetol*. 2011;48:41–53.

309. Schwab KO, Doerfer J, Hallermann K, Krebs A, Schorb E, Krebs K, Winkler K. Marked smoking-associated increase of cardiovascular risk in childhood type 1 diabetes. *Int J Adolesc Med Health*. 2008;20:285–292.

310. Reynolds K, Liese AD, Anderson AM, Dabelea D, Standiford D, Daniels SR, Waitzfelder B, Case D, Loots B, Imperatore G, Lawrence JM. Prevalence of tobacco use and association between cardiometabolic risk factors and cigarette smoking in youth with type 1 or type 2 diabetes mellitus. *J Pediatr*. 2011;158:594–601.

311. Deleted in proof.

312. Mays D, Streisand R, Walker LR, Prokhorov AV, Tercyak KP. Cigarette smoking among adolescents with type 1 diabetes: strategies for behavioral prevention and intervention. *J Diabetes Complications*. 2012;26:148–153.

313. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore HJ, Davey Smith G. Reduced or modified dietary fat for preventing cardiovascular disease. *Cochrane Database Syst Rev*. 2012;5:CD002137.

314. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med*. 2006;166:285–293.

315. Deleted in proof.

316. Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, Pi-Sunyer FX, Ravussin E; Look AHEAD Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. *Diabetes*. 2010;59:627–633.

317. Wheeler ML, Dunbar SA, Jaacks LM, Karmally W, Mayer-Davis EJ, Wylie-Rosett J, Yancy WS Jr. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. *Diabetes Care*. 2012;35:434–445.

318. Smart C, Aslander-van Vliet E, Waldron S. Nutritional management in children and adolescents with diabetes. *Pediatr Diabetes*. 2009;10(suppl 12):100–117.

319. US Department of Agriculture and US Department of Health and Human Services. *Dietary Guidelines for Americans*. 7th ed. Washington, DC: US Government Printing Office; 2010.

320. Lodefalk M, Aman J. Food habits, energy and nutrient intake in adolescents with type 1 diabetes mellitus. *Diabet Med*. 2006;23:1225–1232.

321. Mayer-Davis EJ, Nichols M, Liese AD, Bell RA, Dabelea DM, Johansen JM, Pihoker C, Rodriguez BL, Thomas J, Williams D. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. *J Am Diet Assoc*. 2006;106:689–697.

322. Overby NC, Margeirsdottir HD, Brunborg C, Andersen LF, Dahl-Jorgensen K. The influence of dietary intake and meal pattern on blood glucose control in children and adolescents using intensive insulin treatment. *Diabetologia*. 2007;50:2044–2051.

323. West NA, Hamman RF, Mayer-Davis EJ, D'Agostino RB Jr, Marcovina SM, Liese AD, Zeitler PS, Daniels SR, Dabelea D. Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. *Diabetes Care*. 2009;32:175–180.

324. Helgeson VS, Viccaro L, Becker D, Escobar O, Siminerio L. Diet of adolescents with and without diabetes: trading candy for potato chips? *Diabetes Care*. 2006;29:982–987.

325. Nansel TR, Haynie DL, Lipsky LM, Laffel LM, Mehta SN. Multiple indicators of poor diet quality in children and adolescents with type 1 diabetes are associated with higher body mass index percentile but not glycemic control. *J Acad Nutr Diet*. 2012;112:1728–1735.

326. Papadaki A, Linardakis M, Codrington C, Kafatos A. Nutritional intake of children and adolescents with insulin-dependent diabetes mellitus in Crete, Greece: a case-control study. *Ann Nutr Metab*. 2008;52:308–314.

327. Liese AD, Bortsov A, Gunther AL, Dabelea D, Reynolds K, Standiford DA, Liu L, Williams DE, Mayer-Davis EJ, D'Agostino RB Jr, Bell R, Marcovina S. Association of DASH diet with cardiovascular risk factors in youth with diabetes mellitus: the SEARCH for Diabetes in Youth study. *Circulation*. 2011;123:1410–1417.

328. Barnes TL, Crandell JL, Bell RA, Mayer-Davis EJ, Dabelea D, Liese AD. Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type 2 diabetes mellitus: the SEARCH for Diabetes in Youth Study. *Nutr Diabetes*. 2013;3:e91.

329. Bortsov AV, Liese AD, Bell RA, Dabelea D, D'Agostino RB Jr, Hamman RF, Klingensmith GJ, Lawrence JM, Maahs DM, McKeown R, Marcovina SM, Thomas J, Williams DE, Mayer-Davis EJ. Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes. *Acta Diabetol*. 2011;48:275–282.

330. The NS, Crandell JL, Thomas J, Couch SC, Shah AS, Maahs DM, Dabelea D, Marcovina SM, D'Agostino RB Jr, Mayer-Davis EJ; SEARCH for Diabetes in Youth Study Group. Correlates of medical nutrition therapy and cardiovascular outcomes in youth with type 1 diabetes. *J Nutr Educ Behav*. 2013;45:661–668.

331. Gellar LA, Schrader K, Nansel TR. Healthy eating practices: perceptions, facilitators, and barriers among youth with diabetes. *Diabetes Educ*. 2007;33:671–679.

332. Mehta SN, Haynie DL, Higgins LA, Bucey NN, Rovner AJ, Volkening LK, Nansel TR, Laffel LM. Emphasis on carbohydrates may negatively influence dietary patterns in youth with type 1 diabetes. *Diabetes Care*. 2009;32:2174–2176.

333. Maffeis C, Morandi A, Ventura E, Sabbion A, Contreas G, Tomasselli F, Tommasi M, Fasan I, Costantini S, Pinelli L. Diet, physical, and biochemical characteristics of children and adolescents with type 1 diabetes: relationship between dietary fat and glucose control. *Pediatr Diabetes*. 2012;13:137–146.

334. Colton PA, Olmsted MP, Daneman D, Rydall AC, Rodin GM. Five-year prevalence and persistence of disturbed eating behavior and eating disorders in girls with type 1 diabetes. *Diabetes Care*. 2007;30:2861–2862.

335. Markowitz JT, Lowe MR, Volkening LK, Laffel LM. Self-reported history of overweight and its relationship to disordered eating in adolescent girls with type 1 diabetes. *Diabet Med*. 2009;26:1165–1171.

336. Tse J, Nansel TR, Haynie DL, Mehta SN, Laffel LM. Disordered eating behaviors are associated with poorer diet quality in adolescents with type 1 diabetes. *J Acad Nutr Diet*. 2012;112:1810–1814.

337. Ackard DM, Vik N, Neumark-Sztainer D, Schmitz KH, Hannan P, Jacobs DR Jr. Disordered eating and body dissatisfaction in adolescents with type 1 diabetes and a population-based comparison sample: comparative prevalence and clinical implications. *Pediatr Diabetes*. 2008;9(pt 1):312–319.

338. Howe CJ, Jawad AF, Kelly SD, Lipman TH. Weight-related concerns and behaviors in children and adolescents with type 1 diabetes. *J Am Psychiatr Nurses Assoc*. 2008;13:376–385.

339. Olmsted MP, Colton PA, Daneman D, Rydall AC, Rodin GM. Prediction of the onset of disturbed eating behavior in adolescent girls with type 1 diabetes. *Diabetes Care*. 2008;31:1978–1982.

340. Lawrence JM, Liese AD, Liu L, Dabelea D, Anderson A, Imperatore G, Bell R. Weight-loss practices and weight-related issues among youth with type 1 or type 2 diabetes. *Diabetes Care*. 2008;31:2251–2257.

341. Young V, Eiser C, Johnson B, Brierley S, Epton T, Elliott J, Heller S. Eating problems in adolescents with type 1 diabetes: a systematic review with meta-analysis. *Diabet Med*. 2013;30:189–198.

342. Goebel-Fabbri AE, Fikkan J, Franko DL, Pearson K, Anderson BJ, Weinger K. Insulin restriction and associated morbidity and mortality in women with type 1 diabetes. *Diabetes Care*. 2008;31:415–419.

343. Delahanty L, Kriska A, Edelstein S, Amodei N, Chadwick J, Copeland K, Galvin B, El Ghormli L, Haymond M, Kelsey MM, Lassiter C, Milaszewski K, Syme A, Mayer-Davis E. Self-reported dietary intake of youth with recent onset of type 2 diabetes: results from the TODAY study. *J Acad Nutr Diet*. 2013;113:431–439.

344. Rothman RL, Mulvaney S, Elasy TA, VanderWoude A, Gebretsadik T, Shintani A, Potter A, Russell WE, Schlundt D. Self-management behaviors, racial disparities, and glycemic control among adolescents with type 2 diabetes. *Pediatrics*. 2008;121:e912–e919.

344a. Lukacs A, Mayer K, Juhasz E, Varga B, Fodor B, Barkai L. Reduced physical fitness in children and adolescents with type 1 diabetes. *Pediatr Diabetes*. 2012;13:432–437.

345. Lobelo F, Liese AD, Liu J, Mayer-Davis EJ, D'Agostino RB Jr, Pate RR, Hamman RF, Dabelea D. Physical activity and electronic media use in the SEARCH for diabetes in youth case-control study. *Pediatrics*. 2010;125:e1364–e1371.

346. Shaibi GQ, Faulkner MS, Weigensberg MJ, Fritschi C, Goran MI. Cardiorespiratory fitness and physical activity in youth with type 2 diabetes. *Pediatr Diabetes*. 2008;9:460–463.

347. Williams BK, Guelfi KJ, Jones TW, Davis EA. Lower cardiorespiratory fitness in children with type 1 diabetes. *Diabet Med*. 2011;28:1005–1007.

348. Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 2012;55:542–551.

349. Guelfi KJ, Jones TW, Fournier PA. New insights into managing the risk of hypoglycaemia associated with intermittent high-intensity exercise in individuals with type 1 diabetes mellitus: implications for existing guidelines. *Sports Med*. 2007;37:937–946.

350. Robertson K, Adolfsson P, Scheiner G, Hanas R, Riddell MC. Exercise in children and adolescents with diabetes. *Pediatr Diabetes*. 2009;10(suppl 12):154–168.

351. Rosa JS, Galassetti PR. Altered molecular adaptation to exercise in children with type 1 diabetes: beyond hypoglycemia. *Pediatr Diabetes*. 2009;10:213–226.

352. Aman J, Skinner TC, de Beaufort CE, Swift PG, Aanstoot HJ, Cameron F; Hvidoere Study Group on Childhood Diabetes. Associations between physical activity, sedentary behavior, and glycemic control in a large cohort of adolescents with type 1 diabetes: the Hvidoere Study Group on Childhood Diabetes. *Pediatr Diabetes*. 2009;10:234–239.

353. Galler A, Lindau M, Ernert A, Thalemann R, Raile K. Associations between media consumption habits, physical activity, socioeconomic status, and glycemic control in children, adolescents, and young adults with type 1 diabetes. *Diabetes Care*. 2011;34:2356–2359.

354. Herbst A, Kordonouri O, Schwab KO, Schmidt F, Holl RW. Impact of physical activity on cardiovascular risk factors in children with type 1 diabetes: a multicenter study of 23,251 patients. *Diabetes Care*. 2007;30:2098–2100.

355. Faulkner MS. Cardiovascular fitness and quality of life in adolescents with type 1 or type 2 diabetes. *J Spec Pediatr Nurs*. 2010;15:307–316.

356. Fintini D, Di Giacinto B, Brufani C, Cafiero G, Patera PI, Turchetta A, Giordano U, Nobili V, Pelliccia A, Calzolari A, Cappa M. Impaired energy expenditure despite normal cardiovascular capacity in children with type 1 diabetes. *Horm Res Paediatr*. 2012;78:1–7.

357. Michaliszyn SF, Shaibi GQ, Quinn L, Fritschi C, Faulkner MS. Physical fitness, dietary intake, and metabolic control in adolescents with type 1 diabetes. *Pediatr Diabetes*. 2009;10:389–394.

358. D'hooge R, Hellinckx T, Van Laethem C, Stegen S, De Schepper J, van Aken S, Dewolf D, Calders P. Influence of combined aerobic and resistance training on metabolic control, cardiovascular fitness and quality of life in adolescents with type 1 diabetes: a randomized controlled trial. *Clin Rehabil*. 2011;25:349–359.

359. Faulkner MS, Michaliszyn SF, Hepworth JT. A personalized approach to exercise promotion in adolescents with type 1 diabetes. *Pediatr Diabetes*. 2010;11:166–174.

360. Davis CL, Pollock NK, Waller JL, Allison JD, Dennis BA, Bassali R, Melendez A, Boyle CA, Gower BA. Exercise dose and diabetes risk in overweight and obese children: a randomized controlled trial. *JAMA*. 2012;308:1103–1112.

361. Helgeson VS, Siminerio L, Escobar O, Becker D. Predictors of metabolic control among adolescents with diabetes: a 4-year longitudinal study. *J Pediatr Psychol*. 2009;34:254–270.

362. Hema DA, Roper SO, Nehring JW, Call A, Mandleco BL, Dyches TT. Daily stressors and coping responses of children and adolescents with type 1 diabetes. *Child Care Health Dev*. 2009;35:330–339.

363. Berlin KS, Rabideau EM, Hains AA. Empirically derived patterns of perceived stress among youth with type 1 diabetes and relationships to metabolic control. *J Pediatr Psychol*. 2012;37:990–998.

364. Herzer M, Vesco A, Ingerski LM, Dolan LM, Hood KK. Explaining the family conflict-glycemic control link through psychological variables in adolescents with type 1 diabetes. *J Behav Med*. 2011;34:268–274.

365. Butler JM, Skinner M, Gelfand D, Berg CA, Wiebe DJ. Maternal parenting style and adjustment in adolescents with type I diabetes. *J Pediatr Psychol*. 2007;32:1227–1237.

366. Helgeson VS, Becker D, Escobar O, Siminerio L. Families with children with diabetes: implications of parent stress for parent and child health. *J Pediatr Psychol*. 2012;37:467–478.

367. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A. Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. *Diabetologia*. 2011;54:2483–2493.

368. Reynolds KA, Helgeson VS. Children with diabetes compared to peers: depressed? Distressed? A meta-analytic review. *Ann Behav Med*. 2011;42:29–41.

369. Anderson BJ, Edelstein S, Abramson NW, Katz LE, Yasuda PM, Lavietes SJ, Trief PM, Tollefsen SE, McKay SV, Kringas P, Casey TL, Marcus MD. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. *Diabetes Care*. 2011;34:2205–2207.

370. Helgeson VS, Snyder PR, Escobar O, Siminerio L, Becker D. Comparison of adolescents with and without diabetes on indices of psychosocial functioning for three years. *J Pediatr Psychol*. 2007;32:794–806.

371. de Wit M, Snoek FJ. Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes: results of a web-survey. *Pediatr Diabetes*. 2011;12(pt 1):172–176.

372. Stewart SM, Simmons A, White PC. Somatic items in the assessment of depressive symptoms in pediatric patients with diabetes. *J Behav Med*. 2011;34:112–119.

373. Hilliard ME, Herzer M, Dolan LM, Hood KK. Psychological screening in adolescents with type 1 diabetes predicts outcomes one year later. *Diabetes Res Clin Pract*. 2011;94:39–44.

374. McGrady ME, Hood KK. Depressive symptoms in adolescents with type 1 diabetes: associations with longitudinal outcomes. *Diabetes Res Clin Pract*. 2010;88:e35–e37.

375. Hood KK, Rausch JR, Dolan LM. Depressive symptoms predict change in glycemic control in adolescents with type 1 diabetes: rates, magnitude, and moderators of change. *Pediatr Diabetes*. 2011;12:718–723.

376. Guilfoyle SM, Crimmins NA, Hood KK. Blood glucose monitoring and glycemic control in adolescents with type 1 diabetes: meter downloads versus self-report. *Pediatr Diabetes*. 2011;12:560–566.

377. Stewart SM, Rao U, Emslie GJ, Klein D, White PC. Depressive symptoms predict hospitalization for adolescents with type 1 diabetes mellitus. *Pediatrics*. 2005;115:1315–1319.

378. Gonder-Frederick L, Zrebiec J, Bauchowitz A, Lee J, Cox D, Ritterband L, Kovatchev B, Clarke W. Detection of hypoglycemia by children with type 1 diabetes 6 to 11 years of age and their parents: a field study. *Pediatrics*. 2008;121:e489–e495.

379. Roy MS, Affouf M, Roy A. Six-year incidence of proteinuria in type 1 diabetic African Americans. *Diabetes Care*. 2007;30:1807–1812.

380. McGrady ME, Laffel L, Drotar D, Repaske D, Hood KK. Depressive symptoms and glycemic control in adolescents with type 1 diabetes: mediational role of blood glucose monitoring. *Diabetes Care*. 2009;32:804–806.

381. Jaser SS, Holl MG, Jefferson V, Grey M. Correlates of depressive symptoms in urban youth at risk for type 2 diabetes mellitus. *J Sch Health*. 2009;79:286–292.

382. Akbas S, Karabekiroglu K, Ozgen T, Tasdemir G, Karakurt M, Senses A, Boke O, Aydin M. Association between emotional and behavioral problems and metabolic control in children and adolescents with type 1 diabetes. *J Endocrinol Invest*. 2009;32:325–329.

383. US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement. *Pediatrics*. 2009;123:1223–1228.

384. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med*. 2004;141:846–850.

385. Knutson, KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. *Ann NY Acad Sci*. 2008;1129:287–304.

386. Hayes AL, Xu F, Babineau D, Patel SR. Sleep duration and circulating adipokine levels. *Sleep*. 2011;34:147–152.

387. Martinez-Gomez D, Eisenmann JC, Gomez-Martinez S, Hill EE, Zapatera B, Veiga OL, Marcos A; AFINOS Study Group. Sleep duration and emerging cardiometabolic risk markers in adolescents: the AFINOS study. *Sleep Med*. 2011;12:997–1002.

388. Narang I, Manlhiot C, Davies-Shaw J, Gibson D, Chahal N, Stearne K, Fisher A, Dobbin S, McCrindle BW. Sleep disturbance and cardiovascular risk in adolescents. *CMAJ*. 2012;184:E913–E920.

389. Altman NG, Izci-Balserak B, Schopfer E, Jackson N, Rattanaumpawan P, Gehrman PR, Patel NP, Grandner MA. Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. *Sleep Med*. 2012;13:1261–1270.

390. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J*. 2011;32:1484–1492.

391. Estrada CL, Danielson KK, Drum ML, Lipton RB. Insufficient sleep in young patients with diabetes and their families. *Biol Res Nurs*. 2012;14:48–54.

392. Matyka KA, Crawford C, Wiggs L, Dunger DB, Stores G. Alterations in sleep physiology in young children with insulin- dependent diabetes mellitus: relationship to nocturnal hypoglycemia. *J Pediatr*. 2000;137:233–238.

393. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. *Expert Rev Pharmacoecon Outcomes Res*. 2013;13:123–130.

394. Donga E, van Dijk M, van Dijk JG, Biermasz NR, Lammers GJ, van Kralingen K, Hoogma RP, Corssmit EP, Romijn JA. Partial sleep restriction decreases insulin sensitivity in type 1 diabetes. *Diabetes Care*. 2010;33:1573–1577.

395. Borel AL, Pepin JL, Nasse L, Baguet JP, Netter S, Benhamou PY. Short sleep duration measured by wrist actimetry is associated with deteriorated glycemic control in type 1 diabetes. *Diabetes Care*. 2013;36:2902–2908.

396. Borel AL, Benhamou PY, Baguet JP, Debaty I, Levy P, Pepin JL, Mallion JM. Short sleep duration is associated with a blood pressure nondipping pattern in type 1 diabetes: the DIAPASOM study. *Diabetes Care*. 2009;32:1713–1715.

397. Jauch-Chara K, Schmid SM, Hallschmid M, Born J, Schultes B. Altered neuroendocrine sleep architecture in patients with type 1 diabetes. *Diabetes Care*. 2008;31:1183–1188.

398. Pallayova M, Donic V, Gresova S, Peregrim I, Tomori Z. Do differences in sleep architecture exist between persons with type 2 diabetes and non-diabetic controls? *J Diabetes Sci Technol*. 2010;4:344–352.

399. Perfect MM, Patel PG, Scott RE, Wheeler MD, Patel C, Griffin K, Sorensen ST, Goodwin JL, Quan SF. Sleep, glucose, and daytime functioning in youth with type 1 diabetes. *Sleep*. 2012;35:81–88.

400. Pillar G, Schuscheim G, Weiss R, Malhotra A, McCowen KC, Shlitner A, Peled N, Shehadeh N. Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. *J Pediatr*. 2003;142:163–168.

401. Ly TT, Jones TW, Griffiths A, Dart J, Davis EA, Stick S, Wilson A. Hypoglycemia does not change the threshold for arousal from

402. Gozal D, Capdevila OS, Kheirandish-Gozal L. Metabolic alterations and systemic inflammation in obstructive sleep apnea among non-obese and obese prepubertal children. *Am J Respir Crit Care Med*. 2008;177:1142–1149.

403. O'Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute, part I: the beginning of an era. *Circ Cardiovasc Genet*. 2008;1:51–57.

404. Earle K, Walker J, Hill C, Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. *N Engl J Med*. 1992;326:673–677.

405. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK, Ferrannini E. Parental history of diabetes is associated with increased cardiovascular risk factors. *Arteriosclerosis*. 1989;9:928–933.

406. Orchard TJ, Costacou T. When are type 1 diabetic patients at risk for cardiovascular disease? *Curr Diab Rep*. 2010;10:48–54.

407. Ordovas JM. Genetic links between diabetes mellitus and coronary atherosclerosis. *Curr Atheroscler Rep*. 2007;9:204–210.

408. Parikh NI, Hwang SJ, Larson MG, Cupples LA, Fox CS, Manders ES, Murabito JM, Massaro JM, Hoffmann U, O'Donnell CJ. Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation cohorts. *Circulation*. 2007;116:1473–1481.

409. Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, Szklo M, Greenland P, Blumenthal RS. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation*. 2007;116:619–626.

410. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. *Diabetes Care*. 1998;21:610–614.

411. Purnell JQ, Dev RK, Steffes MW, Cleary PA, Palmer JP, Hirsch IB, Hokanson JE, Brunzell JD. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. *Diabetes*. 2003;52:2623–2629.

412. Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, Dalton RN, Deanfield J, Dunger D; AdDIT Investigators. Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. *Diabetes Care*. 2014;37:805–813.

413. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2007;115:114–126.

414. Gale EA. Declassifying diabetes. *Diabetologia*. 2006;49:1989–1995.

415. Zeitler P. Approach to the obese adolescent with new-onset diabetes. *J Clin Endocrinol Metab*. 2010;95:5163–5170.

416. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. *JAMA*. 1998;280:140–146.

Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus: A Scientific Statement From the American Heart Association

David M. Maahs, Stephen R. Daniels, Sarah D. de Ferranti, Helén L. Dichek, Joseph Flynn, Benjamin I. Goldstein, Aaron S. Kelly, Kristen J. Nadeau, Pamela Martyn-Nemeth, Stavroula K. Osganian, Laurie Quinn, Amy S. Shah and Elaine Urbina

on behalf of the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council for High Blood Pressure Research, and Council on Lifestyle and Cardiometabolic Health

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/130/17/1532

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2014/08/28/CIR.0000000000000094.DC1.html

Supplement 1; Brief Descriptions of On-Going Large Multi-Center Observational and Interventional Research Studies

Studies in Progress: Observational

SEARCH for Diabetes in Youth is an ongoing, multicenter, observational study designed to estimate the population prevalence and incidence of diabetes by type, age, gender, and ethnicity in individuals under age 20 years as well as to describe the clinical characteristics, clinical course, and complications of diabetes and develop practical approaches to diabetes classification[56]. Active surveillance for all cases of physician-diagnosed diabetes, excluding gestational diabetes, is conducted in geographically defined populations located at four sites (Cincinnati, Colorado, Seattle, and South Carolina) and in membership based health plans at two sites (Hawaii and Southern California) using networks of endocrinologists, other health care providers, hospitals, existing pediatric diabetes databases, health plan databases, and administrative databases as well as death certificate searches.   Data are collected at the time of enrollment and annually thereafter and include patient interviews, physical examinations, anthropometry, BP, medical records reviews, and documentation of risk factors for complications and processes of care as well as several laboratory studies for diabetes autoantibodies, C-peptide, HbA1c, blood glucose, lipids, and urine albumin and creatinine. The study was initiated in 2000 and is expected to continue until 2015.

Diabetes Patientien Verlaufsdokumentation (DPV)

Initiated in 1990, the German/Austrian Diabetes Patientien Verlaufsdokumentation (DPV) is a prospective, standardized, multicenter, electronic data acquisition system designed to collect data on the clinical care and health outcomes of adults and children with diabetes[57]. Over 300 participating health care facilities, including hospitals, clinics, diabetes specialized practices, and general practitioner or primary care offices from Germany and Austria presently contribute data, which is used for patient care, quality assurance/benchmarking and epidemiologic and clinical research. De-identified demographic and clinical data that were recorded locally as part of routine outpatient and inpatient care are submitted to a central center for data integrity checking and statistical analyses every 6 months.

Type 1 Diabetes Exchange

The T1D Exchange Clinic Network is a registry of adults and children with T1D and is one of three parts of the T1D Exchange, which was initiated in 2010, in addition to a patient centered on line community (called Glu http://www.t1dexchange.org/core-values-and-mission-statement/glu/) and a biobank to store biological samples for use by researchers[58]. Over 26,000 people with T1D from 70 centers in the U.S. have been enrolled with goals of: 1) identifying and addressing pertinent clinical issues; 2) conducting exploratory/hypothesis generating analyses; and 3) categorizing participants for future clinical studies[58].

Interventional:

The Adolescent type I Diabetes cardio-renal Intervention Trial (AdDIT) is a multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate whether treatment with an angiotensin converting enzyme inhibitor (ACEI) or a statin, alone or in combination, in high risk adolescents with T1D can improve early surrogate markers of diabetic nephropathy and CVD[59]. Clinical centers located in the United Kingdom, Australia, and Canada will recruit 500 adolescents, ages 11-16 years with T1D diagnosed for more than one year who are at high risk for diabetic nephropathy and CVD. Patients will be randomized to receive either Quinapril (ACEI) at 10g daily or Atorvastatin (Statin) at 10 mg daily or combination therapy or placebo in a 2 X 2 factorial design for 3-4 years. The primary aim of the trial is to demonstrate a significant reduction in albumin excretion and the incidence of microalbuminuria. Secondary objectives of the trial will be to determine the effects of treatment on surrogate CV outcomes including endothelial dysfunction, subclinical atherosclerosis, and arterial stiffness, CVD risk factor levels, and CVD risk markers as well as renal function. The trial is scheduled to be completed fall 2013. It will be the first major trial to provide data on the most effective strategy of

managing high risk adolescents with T1D in order to reduce risk for future morbidity and mortality from diabetic nephropathy and CVD.

Treatment Options for Type 2 Diabetes in Adolescents and Youth: TODAY Study
TODAY was a multicenter, randomized-controlled trial studying treatment options in youth with T2D. Participants were recruited from 15 study centers across the US between 2004 and 2009 and followed for a minimum of two years and a maximum of 6 years mean follow-up time was 3.86 years[44, 60]. Eligibility criteria included children from 10 to 17 years of age, diagnosed with T2D within the last 2 years, with negative pancreatic auto-antibodies, sustained c-peptide and a BMI greater than the 85th percentile for age and sex[61]. Of the 1,206 obese subjects screened and considered clinically to have T2D, 118 (9.8%) were positive for GAD-65 and/or insulinoma-associated protein 2 (IA-2) autoantibodies antibodies; of these, 71 (5.9%) were positive for a single antibody, and 47 were positive (3.9%) for both antibodies[61, 62]. Thus, without islet autoantibody analysis, it is difficult to reliably distinguish between T1D and T2D in obese youth.

699 subjects were randomized 1:1:1 between each of three arms: metformin alone, metformin plus rosiglitazone, or metformin plus intensive lifestyle intervention[44]. In the lifestyle arm, participants met with a physical activity and nutrition leader weekly for six months then biweekly for six months, and then quarterly for the remainder of the study, using a lifestyle intervention program designed by the TODAY study specifically for use in low-income and minority youth[63]. The primary endpoint for the study was treatment failure, defined as a HbA1c >8% for 6 months, or sustained metabolic decompensation requiring insulin therapy[60].

The results of TODAY indicate that monotherapy with metformin does not provide sustained control of glycemia in many youth with T2D and suggest that combination therapy will be required. While rosiglitazone appeared most effective in the adolescents in TODAY, in adults, the use of agents in the thiazolidinedione class has now declined due to cardiovascular and bone density safety concerns[64, 65]. However, serious adverse events did not differ between arms in TODAY. Longer-term follow-up of TODAY participants (TODAY2) will provide further insights into complications of youth-onset T2D. In addition, TODAY data argue that early interventions aimed at sustaining beta cell function may be the most beneficial approach to management of T2D.